var title_f3_36_3648="Posterior vaginal wall prolapse 6";
var content_f3_36_3648=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F52823&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F52823&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Repair of posterior vaginal wall prolapse",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 372px; height: 349px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Locations of site-specific defects in the posterior vaginal wall. Defects in the fibromuscularis can be found in the lateral sidewalls (L), midline (M), or in a transverse orientation (T) at the apex or distally near the perineal body.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Walters, MD, Karram, MM. Urogynecology and reconstructive pelvic surgery, 3rd ed, Mosby-Elsevier, 2007. Copyright &copy;2007 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_36_3648=[""].join("\n");
var outline_f3_36_3648=null;
var title_f3_36_3649="Erysipelas buttock";
var content_f3_36_3649=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F78928&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F78928&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erysipelas involving the buttock",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_36_3649=[""].join("\n");
var outline_f3_36_3649=null;
var title_f3_36_3650="Hanks dilators";
var content_f3_36_3650=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F50262&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F50262&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hanks cervical dilators",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 426px; height: 201px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These dilators are sized for progressive cervical dilation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_36_3650=[""].join("\n");
var outline_f3_36_3650=null;
var title_f3_36_3651="Angiography during septal ablation for HCM";
var content_f3_36_3651=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F58311&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F58311&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Angiography during septal ablation for HCM",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 404px; height: 399px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Alcohol septal ablation in a patient with hypertrophic cardiomyopathy (HCM). Right anterior oblique cranial coronary angiography shows (top left) baseline appearance of the first septal perforator (arrow; not shown in this still image but seen on cine was clear \"milking\" of this septal branch during systole owing to the compression of septal contraction), (bottom left) inflation of angioplasty balloon in that branch, (bottom right) contrast injection via balloon central lumen, and (top right) final result with obliteration of septal perforator without compromise or embolization of the left anterior descending artery.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Baim DS. Grossman's Cardiac Catheterization, Angiography, and Intervention, Seventh Ed, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_36_3651=[""].join("\n");
var outline_f3_36_3651=null;
var title_f3_36_3652="Methyltestosterone: Drug information";
var content_f3_36_3652=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Methyltestosterone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?41/23/42356?source=see_link\">",
"    see \"Methyltestosterone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F195469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Android&reg;;",
"     </li>",
"     <li>",
"      Methitest&trade;;",
"     </li>",
"     <li>",
"      Testred&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F195485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Androgen",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F195472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Hypogonadism (male), delayed puberty (males):",
"     </b>",
"     Oral: Individualize dose based on response and tolerability.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Androgen deficiency (males):",
"     </b>",
"     Oral: 10-50 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Breast cancer (females):",
"     </b>",
"     Oral: 50-200 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F195473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F195457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Android&reg;: 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Testred&reg;: 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Methitest&trade;: 10 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F195442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F195487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-III",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F195459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Male: Hypogonadism; delayed puberty; impotence and climacteric symptoms",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Female: Palliative treatment of metastatic breast cancer",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F11515684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypogonadism (male); delayed puberty (male)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F195493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       MethylTESTOSTERone may be confused with medroxyPROGESTERone, methylPREDNISolone",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - weak).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F195483\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Male:",
"     </b>",
"     Gynecomastia, impotence, oligospermia (at high doses), priapism, prostatic carcinoma, prostatic hyperplasia, testicular atrophy, virilism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Female:",
"     </b>",
"     Atrophy, breast soreness, hirsutism, menstrual problems (amenorrhea), virilism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, depression, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Acne, &ldquo;male pattern&rdquo; baldness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypercalcemia, hypercholesterolemia, libido (changes in)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Polycythemia, suppression of clotting factors",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Cholestatic hepatitis, hepatic dysfunction, hepatic necrosis, hepatocellular neoplasm (rare), jaundice, liver function tests (abnormal), peliosis hepatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylactoid reactions (rare)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F195462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Males with carcinoma of the breast or the prostate (known or suspected); women who are or may become pregnant",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F195446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic effects: Prolonged use and/or high doses may cause peliosis hepatis or liver cell tumors which may not be apparent until liver failure or intra-abdominal hemorrhage develops. Discontinue in case of cholestatic hepatitis with jaundice or abnormal liver function tests.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Breast cancer: Use with caution in patients with breast cancer; may cause hypercalcemia by stimulating osteolysis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; monitor carefully.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Edematous conditions: Use with caution in patients with conditions influenced by edema (eg, cardiovascular disease, migraine, seizure disorder, renal impairment); may cause fluid retention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: May be inappropriate in this age group due to potential risk of cardiac problems and contraindication for use in men with prostate cancer; in general, avoid use in older adults except in the setting of moderate-to-severe hypogonadism (Beers Criteria). In addition, elderly patients may be at greater risk for fluid retention and transaminase elevations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: May accelerate bone maturation without producing compensatory gain in linear growth in children; in prepubertal children perform radiographic examination of the hand and wrist every 6 months to determine the rate of bone maturation and to assess the effect of treatment on the epiphyseal centers.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Women: Discontinue with evidence of mild virilization in women.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F195451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Androgens may enhance the hepatotoxic effect of CycloSPORINE (Systemic). Androgens may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Androgens may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F195452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13388443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use is contraindicated in women who are or may become pregnant. May cause androgenic effects to the female fetus; clitoral hypertrophy, labial fusion, urogenital sinus defect, vaginal atresia, and ambiguous genitalia have been reported.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F195475\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F195463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Android Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $1854.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Testred Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $2825.87",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F195454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In prepubertal children, perform radiographic examination of the hand and wrist every 6 months to determine the rate of bone maturation and to assess the effect of treatment on the epiphyseal centers.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F195464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Build (TW);",
"     </li>",
"     <li>",
"      Gynosterone (IL);",
"     </li>",
"     <li>",
"      Mesteron (PL);",
"     </li>",
"     <li>",
"      Testormon (PT);",
"     </li>",
"     <li>",
"      Testotonic B (IL);",
"     </li>",
"     <li>",
"      Testovis (IT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F195445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulates receptors in organs and tissues to promote growth and development of male sex organs and maintains secondary sex characteristics in androgen-deficient males",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F195461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/36/3652/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9640 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-3918385851-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_36_3652=[""].join("\n");
var outline_f3_36_3652=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195469\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195485\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195472\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195473\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195457\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195442\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195487\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195459\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11515684\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195493\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195483\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195462\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195446\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299703\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195451\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195452\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13388443\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195475\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195463\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195454\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195464\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195445\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195461\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9640\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9640|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?41/23/42356?source=related_link\">",
"      Methyltestosterone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_36_3653="Amlodipine and olmesartan: Patient drug information";
var content_f3_36_3653=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Amlodipine and olmesartan: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/26/12711?source=see_link\">",
"     see \"Amlodipine and olmesartan: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F5528405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Azor&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10012722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700281",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take if you are pregnant. Use during pregnancy may cause birth defects or loss of the unborn baby. If you get pregnant or plan on getting pregnant while taking this drug, call your doctor right away.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701506",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to amlodipine, olmesartan, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3915366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes) and are taking aliskiren.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697627",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697100",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a salt substitute that has potassium, potassium-sparing diuretics, or potassium, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High potassium level. Signs include feeling weak, lightheaded, dizzy, feel like passing out, or have numbness or tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in the arms or legs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698395",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Kidney function that gets worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698670",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you get pregnant while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10012727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10012732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11968 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-210.101.131.231-3DC0084E0B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_36_3653=[""].join("\n");
var outline_f3_36_3653=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5528405\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012722\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012724\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012723\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012728\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012729\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012731\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012726\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012727\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012732\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012733\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/26/12711?source=related_link\">",
"      Amlodipine and olmesartan: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_36_3654="Diphtheria tetanus toxoids acellular pertussis inactivated poliovirus haemophilus influenzae type b conjugate vaccine: Pediatric drug information";
var content_f3_36_3654=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Diphtheria tetanus toxoids acellular pertussis inactivated poliovirus haemophilus influenzae type b conjugate vaccine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?8/32/8710?source=see_link\">",
"    see \"Diphtheria tetanus toxoids acellular pertussis inactivated poliovirus haemophilus influenzae type b conjugate vaccine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?9/40/9858?source=see_link\">",
"    see \"Diphtheria tetanus toxoids acellular pertussis inactivated poliovirus haemophilus influenzae type b conjugate vaccine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F14456818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Pentacel&reg; Shortage Dosing Guidelines; Updated",
"     </span>",
"     <span class=\"collapsible-date\">",
"      October 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The Center for Disease Control and Prevention (CDC) has issued guidelines for vaccinating children during the Pentacel&reg; and Daptacel&reg; shortage. Sanofi Pasteur expects a shortage of these vaccines to continue through March 2013.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Guidelines may be found on the following CDC website:",
"       <a href=\"file://www.cdc.gov/vaccines/vac-gen/shortages/downloads/pentacel-guidance.pdf\" target=\"_blank\">",
"        file://www.cdc.gov/vaccines/vac-gen/shortages/downloads/pentacel-guidance.pdf",
"       </a>",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6215227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Pentacel&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9748134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Pediacel&reg;;",
"     </li>",
"     <li>",
"      Pentacel&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F6788507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vaccine",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F6788515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/32/8710?source=see_link\">",
"      see \"Diphtheria tetanus toxoids acellular pertussis inactivated poliovirus haemophilus influenzae type b conjugate vaccine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Primary Immunization:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants and Children 6 weeks to &le;4 years: I.M.: 0.5 mL per dose administered at 2, 4, 6, and 15-18 months of age (total of 4 doses). The first dose may be administered as early as 6 weeks of age. Following completion of the 4-dose series, children should receive a dose of DTaP vaccine at 4-6 years of age (Daptacel&reg; recommended due to same pertussis antigen used in both products).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Per the ACIP, polio vaccine should not be administered more frequently than 4 weeks apart. Use of the minimum age and minimum intervals during the first 6 months of life should only be done when the vaccine recipient is at risk for imminent exposure to circulating poliovirus (shorter intervals and earlier start dates may lead to lower seroconversion). Pentacel&reg; is not indicated for the polio booster dose given at 4-6 years of age; Kinrix&reg; or IPV should be used.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children previously vaccinated with &ge;1 dose of Daptacel&reg; or IPV vaccines: Pentacel&reg; may be used to complete the first 4 doses of the DTaP or IPV series in children scheduled to receive the other components in the vaccine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children previously vaccinated with &ge;1 dose of",
"     <i>",
"      Haemophilus b",
"     </i>",
"     Conjugate vaccine: Pentacel&reg; may be used to complete the series in children scheduled to receive the other components in the vaccine; however, if different brands of",
"     <i>",
"      Haemophilus b",
"     </i>",
"     Conjugate vaccine are administered to complete the series, 3 primary immunizing doses are needed, followed by a booster dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Completion of 3 doses of Pentacel&reg; provides primary immunization against diphtheria, tetanus,",
"     <i>",
"      H. influenzae",
"     </i>",
"     type B, and poliomyelitis. Completion of the 4-dose series with Pentacel&reg; provides primary immunization against pertussis. It also provides a booster vaccination against diphtheria, tetanus,",
"     <i>",
"      H. influenzae",
"     </i>",
"     type B, and poliomyelitis.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F6215235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, suspension:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Pentacel&reg;: Diphtheria toxoid 15 Lf, tetanus toxoid 5 Lf, acellular pertussis antigens [pertussis toxin detoxified 20 mcg, filamentous hemagglutinin 20 mcg, pertactin 3 mcg, fimbriae (types 2 and 3) 5 mcg], type 1poliovirus 40 D-antigen units; type 2 poliovirus 8 D-antigen units; type 3 poliovirus 32 D-antigen units, and",
"     <i>",
"      Haemophilus",
"     </i>",
"     b capsular polysaccharide 10 mcg [bound to tetanus toxoid 24 mcg] per 0.5 mL (0.5 mL) [contains albumin, aluminum, neomycin, polymyxin B sulfate, and polysorbate 80; supplied in two vials, one containing DTaP-IPV liquid and one containing Hib powder]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F6215229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F6788516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pentacel&reg; is supplied in two vials, one containing DTaP-IPV liquid and one containing Hib powder. First, gently shake vial containing DTaP-IPV component; withdraw liquid contents, and inject into vial containing Hib powder; gently swirl until uniform, cloudy suspension results.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Administer I.M. in the anterolateral aspect of thigh in children &lt;1 year of age or deltoid muscle of upper arm in older children. Do not administer to gluteal area or areas near a major nerve trunk;",
"     <b>",
"      not for I.V. or SubQ administration",
"     </b>",
"     . Do not administer additional vaccines or immunoglobulins at the same site or using the same syringe.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     U.S. law requires that the date of administration, name of the vaccine manufacturer, lot number of vaccine, and the administering person's name, title, and address be entered into the patient's permanent medical record.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F6788514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store under refrigeration of 2&deg;C to 8&deg;C (35&deg;F to 46&deg;F); do not freeze. Discard if frozen.  Use immediately after reconstitution.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F6788508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Active immunization against diphtheria, tetanus, pertussis, poliomyelitis, and invasive disease caused by",
"     <i>",
"      H. influenzae",
"     </i>",
"     type b in infants (at least 6 weeks of age) and children (prior to fifth birthday) (FDA approved in ages 6 weeks through 4 years)",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Advisory Committee on Immunization Practices (ACIP) states that Pentacel&reg; (DTaP-IPV/Hib) may be used to provide the recommended DTaP, IPV, and Hib immunization in children &lt;5 years of age. Whenever feasible, the same manufacturer should be used to provide the pertussis component; however, vaccination should not be deferred if a specific brand is not known or is not available.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8092360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Pentacel&reg; is supplied in two vials, one containing DTaP-IPV liquid and one containing Hib powder, which must be mixed together in order to administer the recommended vaccine components.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F6783404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      All serious adverse reactions must be reported to the U.S. Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967 or online at",
"      <a href=\"https://vaers.hhs.gov/esub/index\" target=\"_blank\">",
"       https://vaers.hhs.gov/esub/index",
"      </a>",
"      .",
"     </b>",
"     In Canada, adverse reactions may be reported to local provincial/territorial health agencies or to the Vaccine Safety Section at Public Health Agency of Canada (1-866-844-0018).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Central nervous system: Crying (inconsolable), fever &ge;38&deg;C, fussiness/irritability, lethargy/decreased activity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site reactions: Arm circumference increase &gt;5 mm, redness &gt;5 mm, swelling &gt;5 mm, tenderness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Anaphylaxis/anaphylactic reaction, apnea, appetite decreased, asthma, bronchiolitis, consciousness decreased, cough, cyanosis, dehydration, diarrhea, encephalopathy, erythema, gastroenteritis, hypersensitivity reactions, hypotonia, hypotonic-hyporesponsive episodes, injection site reactions (abscess, extensive swelling of injected limb, inflammation, mass), pallor, pneumonia, screaming, seizure, skin discoloration, somnolence, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F6788510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any component including neomycin, polymyxin B; encephalopathy occurring within 7 days of administration of a previous dose of a pertussis-containing vaccine that is not attributable to another cause; progressive neurological disorder, including infantile spasms, uncontrolled epilepsy, or progressive encephalopathy (pertussis vaccine should be withheld until the clinical condition has stabilized)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F9559870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Immunization should be delayed during the course of an acute severe febrile illness; may administer to patients with mild acute illness (with or without fever). Use with caution in severely immunocompromised patients (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy, including high-dose corticosteroids); may have a reduced response to vaccination and vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval (CDC, 2011). In general, household and close contacts of persons with altered immunocompetence may receive all age-appropriate vaccines.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A family history of seizures is not a contraindication to use of DTaP. Administer with caution to patients with thrombocytopenia or any coagulation disorder that would be compromised by I.M. injection; if the patient receives antihemophilia or other similar therapy, I.M. injection can be scheduled shortly after such therapy is administered. Antipyretics have not been shown to prevent febrile seizures. Antipyretics may be used to treat fever or discomfort following vaccination (CDC, 2011). One study reported that routine prophylactic administration of acetaminophen to prevent fever due to vaccines has been shown to decrease the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F6788511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Immediate treatment for anaphylactoid or acute hypersensitivity reactions should be available during vaccine use. Subsequent vaccination with a pertussis-containing vaccine should be carefully considered if the following reactions occur with a temporal relationship to a previous dose of DTaP: Temperature &ge;40.5&deg;C (105&deg;F) within 48 hours, not attributable to another identifiable cause; collapse or shock-like state (hypotonic-hyporesponsive episode) within 48 hours; persistent crying lasting &ge;3 hours within 48 hours; or convulsions with or without fever, occurring within 3 days. Guillain-Barr&eacute; syndrome occurring within 6 weeks of vaccines containing tetanus toxoid has been reported. Tetanus toxoid containing vaccine (including emergency doses) should not be given more frequently than every 10 years in patients who have experienced a serious arthus-type hypersensitivity reaction following a prior use of tetanus toxoid; these patients generally have high serum antitoxin levels. Syncope has been reported with use of injectable vaccines and may be accompanied by transient visual disturbances, weakness, or tonic-clonic movements. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs. Apnea has occurred following intramuscular vaccine administration in premature infants; consider clinical status implications. Injection contains polysorbate 80 (Tween 80&reg;) which may cause allergic reactions in susceptible individuals. In premature neonates, thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported after receiving parenteral products containing polysorbate 80 (Alade, 1986; CDC, 1984).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6265257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cytarabine (Liposomal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F6783395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6783396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted for this combination product. This product is not indicated for use in women of childbearing age.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13929404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Observe for syncope for 15 minutes following administration. If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9559871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Promotes active immunity to diphtheria, tetanus, pertussis, poliovirus (types 1, 2, and 3) and",
"     <i>",
"      Haemophilus influenzae",
"     </i>",
"     type b by inducing production of specific antibodies and antitoxins",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F9559882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/40/9858?source=see_link\">",
"      see \"Diphtheria tetanus toxoids acellular pertussis inactivated poliovirus haemophilus influenzae type b conjugate vaccine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause increased sleeping, restlessness, fussiness, decreased appetite, or fever; use antipyretic if directed by healthcare provider. May cause some redness, pain, or swelling at injection site; consult healthcare provider if excessive or persistent. Notify healthcare provider immediately of any excessive or persistent reactions (eg, fever &gt;105&deg;F within 48 hours, inconsolable crying that occurs within 48 hours and lasts 3 hours, seizures that occur within 3 days).",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F6788517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contains the following three pertussis antigens: Inactivated pertussis toxin (PT), filamentous hemagglutinin (FHA), and pertactin. Contains the same diphtheria, tetanus toxoids, and pertussis antigens found in Daptacel&reg;; the same poliovirus antigens found in IPOL&reg;; the same Hib-PRP found in ActHIB&reg;.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     In order to maximize vaccination rates, the ACIP recommends simultaneous administration of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single visit, unless contraindications exist. The use of combination vaccines is generally preferred over separate injections, taking into consideration provider assessment, patient preference, and potential adverse events.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     For additional information, please refer to the following website:",
"     <a href=\"file://www.cdc.gov/vaccines/vpd-vac/\" target=\"_blank\">",
"      file://www.cdc.gov/vaccines/vpd-vac/",
"     </a>",
"     .",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      AAP Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures American Academy of Pediatrics, \"Febrile Seizures: Clinical Practice Guideline for the Long-Term Management of the Child With Simple Febrile Seizures,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 121(6):1281-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/36/3654/abstract-text/18519501/pubmed\" id=\"18519501\" target=\"_blank\">",
"        18519501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Alade SL, Brown RE, and Paquet A Jr, \"Polysorbate 80 and E-Ferol Toxicity,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1986, 77(4):593-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/36/3654/abstract-text/3960626/pubmed\" id=\"3960626\" target=\"_blank\">",
"        3960626",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Licensure of a Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, and",
"      <i>",
"       Haemophilus",
"      </i>",
"      B Conjugate Vaccine and Guidance for Use in Infants and Children,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2008, 57(39):1079-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/36/3654/abstract-text/18830213/pubmed\" id=\"18830213\" target=\"_blank\">",
"        18830213",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Recommendations of the Advisory Committee on Immunization Practices (ACIP): General Recommendations on Immunization,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/36/3654/abstract-text/21293327/pubmed\" id=\"21293327\" target=\"_blank\">",
"        21293327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Unusual Syndrome With Fatalities Among Premature Infants: Association With a New Intravenous Vitamin E Product,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 1984, 33(14):198-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/36/3654/abstract-text/6423951/pubmed\" id=\"6423951\" target=\"_blank\">",
"        6423951",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Syncope After Vaccination-United States, January 2005-July 2007,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2008, 2;57(17):457-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/36/3654/abstract-text/18451756/pubmed\" id=\"18451756\" target=\"_blank\">",
"        18451756",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Updated Recommendations of the Advisory Committee on Immunization Practices (ACIP) Regarding Routine Poliovirus Vaccination,&rdquo;",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2009, 58(30):829-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/36/3654/abstract-text/19661857/pubmed\" id=\"19661857\" target=\"_blank\">",
"        19661857",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prymula R, Siegrist CA, Chlibek R, et al, \"Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 374(9698):1339-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/36/3654/abstract-text/19837254/pubmed\" id=\"19837254\" target=\"_blank\">",
"        19837254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13115 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-190.81.197.98-74C7246191-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_36_3654=[""].join("\n");
var outline_f3_36_3654=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14456818\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6215227\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9748134\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6788507\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6788515\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6215235\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6215229\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6788516\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6788514\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6788508\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8092360\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6783404\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6788510\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9559870\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6788511\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299218\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6265257\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6783395\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6783396\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13929404\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9559871\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9559882\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6788517\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13115\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13115|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/32/8710?source=related_link\">",
"      Diphtheria tetanus toxoids acellular pertussis inactivated poliovirus haemophilus influenzae type b conjugate vaccine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/40/9858?source=related_link\">",
"      Diphtheria tetanus toxoids acellular pertussis inactivated poliovirus haemophilus influenzae type b conjugate vaccine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_36_3655="Insulin aspart protamine and insulin aspart: Drug information";
var content_f3_36_3655=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Insulin aspart protamine and insulin aspart: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?8/2/8229?source=see_link\">",
"    see \"Insulin aspart protamine and insulin aspart: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/50/5926?source=see_link\">",
"    see \"Insulin aspart protamine and insulin aspart: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2169301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      NovoLOG&reg; Mix 70/30;",
"     </li>",
"     <li>",
"      NovoLOG&reg; Mix 70/30 FlexPen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F4782805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      NovoMix&reg; 30",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F2136162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Insulin, Combination",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F2136552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Insulin aspart protamine is an intermediate-acting insulin and insulin aspart is a rapid-acting insulin administered by SubQ injection. Insulin aspart protamine and insulin aspart combination products are approximately equipotent to insulin NPH and insulin regular combination products with a similar duration of activity, but with a more rapid onset. With combination insulin products, the proportion of rapid-acting to long-acting insulin is fixed; basal vs prandial dose adjustments cannot be made. Fixed ratio insulins (such as insulin aspart protamine and insulin aspart combination) are typically administered as 2 daily doses with each dose intended to cover two meals and a snack. Because of variability in the peak effect and individual patient variability in activities, meals, etc, it may be more difficult to achieve complete glycemic control using fixed combinations of insulins; frequent monitoring and close medical supervision may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      General insulin dosing:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Diabetes mellitus, type 1:",
"     </b>",
"     SubQ:",
"     <b>",
"      Note:",
"     </b>",
"     Multiple daily doses are utilized and guided by blood glucose monitoring. Combinations of different insulin formulations are commonly used. The daily doses presented below are expressed as the",
"     <b>",
"      total units/kg/day of all insulin formulations combined.",
"     </b>",
"     Insulin aspart protamine and insulin aspart combination product is",
"     <b>",
"      not",
"     </b>",
"     intended for initial therapy; basal insulin requirements should be established",
"     <b>",
"      first",
"     </b>",
"     to direct dosing of combination insulin products.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Usual maintenance range:",
"     </b>",
"     0.5-1 units/kg/day in divided doses. An estimate of anticipated needs may be based on body weight and/or activity factors as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Adolescents: May require &le;1.2 units/kg/day during growth spurts",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Nonobese: 0.4-0.6 units/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Obese: 0.8-1.2 units/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Division of daily insulin requirement (\"conventional therapy\"):",
"     </b>",
"     Generally, 50% to 75% of the daily insulin dose is given as an intermediate- or long-acting form of insulin (in 1-2 daily injections). The remaining portion of the 24-hour insulin requirement is divided and administered as either regular insulin or a rapid-acting form of insulin at the same time before breakfast and dinner.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Adjustment of dose:",
"     </b>",
"     Dosage must be titrated to achieve glucose control and avoid hypoglycemia. Adjust dose to maintain premeal and bedtime glucose in target range. Since combinations of agents are frequently used, dosage adjustment must address the individual component of the insulin regimen which most directly influences the blood glucose value in question, based on the known onset and duration of the insulin component. Treatment and monitoring regimens must be individualized. Also see Additional Information or Pharmacotherapy Pearls.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Diabetes mellitus, type 2:",
"     </b>",
"     SubQ: Augmentation therapy (patients for which diet, exercise, weight reduction, and oral hypoglycemic agents have not been adequate):",
"     <b>",
"      Note:",
"     </b>",
"     Insulin aspart protamine and insulin aspart combination product is",
"     <b>",
"      not",
"     </b>",
"     intended for initial therapy; basal insulin requirements should be established",
"     <b>",
"      first",
"     </b>",
"     to direct dosing of combination insulin products. Dosage must be carefully adjusted.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F2309882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F2136553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; insulin requirements may be reduced due to changes in insulin clearance or metabolism; monitor blood glucose closely.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F8102569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; insulin requirements may be reduced due to changes in insulin clearance or metabolism; monitor blood glucose closely.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2104231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, suspension:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     NovoLOG&reg; Mix 70/30: Insulin aspart protamine suspension 70% [intermediate acting] and insulin aspart solution 30% [rapid acting]: 100 units/mL (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     NovoLOG&reg; Mix 70/30 FlexPen&reg;: Insulin aspart protamine suspension 70% [intermediate acting] and insulin aspart solution 30% [rapid acting]: 100 units/mL (3 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F2343844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F2136554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     SubQ administration: In order to properly resuspend the insulin, vials and prefilled pens should be gently rolled between the palms ten times; in addition, prefilled pens should be inverted 180&deg; ten times. Properly resuspended insulin should look uniformly cloudy or milky; do not use if any white insulin substance remains at the bottom of the container, if any clumps are present, if the insulin remains clear after adequate mixing, or if white particles are stuck to the bottom or wall of the container. Cold injections should be avoided. Insulin aspart protamine and insulin aspart combination products should be administered within 15 minutes before a meal (type 1 diabetes) or 15 minutes before or after a meal (type 2 diabetes); typically given twice daily. SubQ administration is usually made into the thighs, arms, buttocks, or abdomen; rotate injection sites. Do not dilute or mix with any other insulin formulation or solution; not recommended for use in external SubQ insulin infusion pump.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F2136543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Insulin detemir, insulin glargine, insulin glulisine, insulin lispro, insulin NPH, insulin regular.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F2136514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of type 1 diabetes mellitus (insulin dependent, IDDM) and type 2 diabetes mellitus (noninsulin dependent, NIDDM) to improve glycemic control",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F2136512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       NovoLOG&reg; Mix 70/30 may be confused with HumaLOG&reg; Mix 75/25&trade;, HumuLIN&reg; 70/30, NovoLIN&reg; 70/30, NovoLOG&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"       <b>",
"        <i>",
"         Due to the number of insulin preparations, it is essential to identify/clarify the type of insulin to be used.",
"        </i>",
"       </b>",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Cross-contamination may occur if insulin pens are shared among multiple patients. Steps should be taken to prohibit sharing of insulin pens.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F2176662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Palpitation, pallor, peripheral edema, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fatigue, headache, hypothermia, loss of consciousness, mental confusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash, redness, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypoglycemia, hypokalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Hunger, nausea, numbness of mouth, weight gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site reaction (including edema, itching, pain or warmth, stinging), lipoatrophy, lipodystrophy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle weakness, paresthesia, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Transient presbyopia or blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, antibodies to insulin (no change in efficacy), diaphoresis, local allergy, systemic allergic symptoms",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F2138088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any component of the formulation; during episodes of hypoglycemia",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F2136517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypoglycemia: The most common adverse effect of insulin is hypoglycemia. The timing of hypoglycemia differs among various insulin formulations. Hypoglycemia may result from increased work or exercise without eating; use of long-acting insulin preparations (eg, insulin detemir, insulin glargine) may delay recovery from hypoglycemia. Profound and prolonged episodes of hypoglycemia may result in convulsions, unconsciousness, temporary or permanent brain damage or even death. Insulin requirements may be altered during illness, emotional disturbances or other stressors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypokalemia: Insulin (especially I.V. insulin) causes a shift of potassium from the extracellular space to the intracellular space, possibly producing hypokalemia. If left untreated, hypokalemia may result in respiratory paralysis, ventricular arrhythmia and even death. Use with caution in patients at risk for hypokalemia (eg, loop diuretic use). Monitor serum potassium and supplement potassium when necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment. Dosage requirements may be reduced.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment. Dosage requirements may be reduced.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration: Insulin aspart protamine and insulin aspart premixed combination products are",
"     <b>",
"      NOT",
"     </b>",
"     intended for I.V. or I.M. administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Diabetes mellitus: The general objective of exogenous insulin therapy is to approximate the physiologic pattern of insulin secretion which is characterized by two distinct phases. Phase 1 insulin secretion suppresses hepatic glucose production and phase 2 insulin secretion occurs in response to carbohydrate ingestion; therefore, exogenous insulin therapy may consist of basal insulin (eg, intermediate- or long-acting insulin or via continuous subcutaneous insulin infusion [CSII]) and/or preprandial insulin (eg, short- or rapid-acting insulin). Patients with type 1 diabetes do not produce endogenous insulin; therefore, these patients require both basal and preprandial insulin administration. Patients with type 2 diabetes retain some beta-cell function in the early stages of their disease; however, as the disease progresses, phase 1 insulin secretion may become completely impaired and phase 2 insulin secretion becomes delayed and/or inadequate in response to meals. Therefore, patients with type 2 diabetes may be treated with oral antidiabetic agents, basal insulin, and/or preprandial insulin depending on the stage of disease and current glycemic control. Since treatment regimens often consist of multiple agents, dosage adjustments must address the specific phase of insulin release that is primarily contributing to the patient&rsquo;s impaired glycemic control. Treatment and monitoring regimens must be individualized.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Patient education: Diabetes self-management education (DSME) is essential to maximize the effectiveness of therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8102566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6221026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents (Thiazolidinedione): Insulin may enhance the fluid-retaining effect of Antidiabetic Agents (Thiazolidinedione).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the hypoglycemic effect of Insulin.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Edetate CALCIUM Disodium: May enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Edetate Disodium: May enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: May enhance the adverse/toxic effect of other Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Luteinizing Hormone-Releasing Hormone Analogs: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: May enhance the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Insulin may enhance the hyperglycemic effect of Quinolone Antibiotics. Insulin may enhance the hypoglycemic effect of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents. Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: May diminish the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F8102567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethanol: Use caution with ethanol; may increase risk of hypoglycemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Use caution with alfalfa, aloe, bilberry, bitter melon, burdock, celery, damiana, fenugreek, garcinia, garlic, ginger, ginseng (American), gymnema, marshmallow, stinging nettle; may increase risk of hypoglycemia.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F2136515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2137901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Biphasic insulin aspart (insulin aspart protamine suspension 70% [intermediate acting] and insulin aspart solution 30% [rapid acting]) was found to be comparable to biphasic human insulin (Insulin NPH suspension 70% [intermediate acting] and insulin regular solution 30% [short acting]) in a pilot study of women with gestational diabetes mellitus. All pregnancies have a background risk of adverse outcome; this risk is increased in pregnancies complicated by hyperglycemia and may be decreased with good metabolic control. Most available information for use of insulin aspart in pregnancy is from studies using the rapid action solution.  Refer to Insulin Aspart monograph for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F2136516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F2137818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if insulin aspart distributes into breast milk. Endogenous insulin can be found in breast milk. Plasma glucose concentrations in the mother affect glucose concentrations in breast milk. The gastrointestinal tract destroys insulin when administered orally; therefore, insulin is not expected to be absorbed intact by the breast-feeding infant. All types of insulin are safe for use while breast-feeding. Due to increased calorie expenditure, women with diabetes may require less insulin while nursing.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F8102570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Individualized medical nutrition therapy (MNT) based on ADA recommendations is an integral part of therapy.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F3422165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (NovoLOG Mix 70/30 FlexPen Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     (70-30) 100 units/mL (3 mL): $65.67",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (NovoLOG Mix 70/30 Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     (70-30) 100 units/mL (10 mL): $176.35",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F8102687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Diabetes mellitus: Plasma glucose, electrolytes, Hb A",
"     <sub>",
"      1c",
"     </sub>",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F8102568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Therapeutic, serum insulin (fasting): 5-20 &mu;IU/mL (SI: 35-145 pmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Glucose, fasting:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Newborns: 60-110 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 60-110 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Elderly: 100-180 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Recommendations for glycemic control in nonpregnant adults with diabetes mellitus (ADA, 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     : &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     goal may be targeted based on patient-specific characteristics)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Preprandial capillary plasma glucose: 70-130 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak postprandial capillary plasma glucose: &lt;180 mg/dL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Novomix 30 (AR, AT, AU, BE, BR, CH, CN, CO, CZ, DE, DK, EE, ES, GB, GR, HK, ID, IE, IL, IN, MY, NO, NZ, PH, PK, PT, RU, SG, TH, TR, TW, UY);",
"     </li>",
"     <li>",
"      Novomix 50 (BE, CZ, EE, IL);",
"     </li>",
"     <li>",
"      Novomix 70 (BE, CZ, EE, IL, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F2136544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Insulin aspart protamine and insulin aspart is an intermediate-acting combination insulin product with a more rapid onset and similar duration of action as compared to that of insulin NPH and insulin regular combination products. Insulin acts via specific membrane-bound receptors on target tissues to regulate metabolism of carbohydrate, protein, and fats. Target organs for insulin include the liver, skeletal muscle, and adipose tissue.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Within the liver, insulin stimulates hepatic glycogen synthesis. Insulin promotes hepatic synthesis of fatty acids, which are released into the circulation as lipoproteins. Skeletal muscle effects of insulin include increased protein synthesis and increased glycogen synthesis. Within adipose tissue, insulin stimulates the processing of circulating lipoproteins to provide free fatty acids, facilitating triglyceride synthesis and storage by adipocytes; also directly inhibits the hydrolysis of triglycerides. In addition, insulin stimulates the cellular uptake of amino acids and increases cellular permeability to several ions, including potassium, magnesium, and phosphate. By activating sodium-potassium ATPases, insulin promotes the intracellular movement of potassium.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Normally secreted by the pancreas, insulin products are manufactured for pharmacologic use through recombinant DNA technology using either",
"     <i>",
"      E. coli",
"     </i>",
"     or",
"     <i>",
"      Saccharomyces cerevisiae",
"     </i>",
"     . Insulins are categorized based on the onset, peak, and duration of effect (eg, rapid-, short-, intermediate-, and long-acting insulin).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F2136546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Rate of absorption, onset, and duration of activity may be affected by site of injection, exercise, presence of lipodystrophy, local blood supply, and/or temperature.",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Onset of action: 10-20 minutes",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;\">",
"     Peak effect: 1-4 hours",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Duration: 18-24 hours",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Protein binding: &le;9%",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Half-life elimination: ~8-9 hours",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Time to peak, plasma: 1-1.5 hours",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl 1):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/36/3655/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Davies M, Storms F, Shutler S, et al, &ldquo;Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2005, 28(6):1282-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/36/3655/abstract-text/15920040/pubmed\" id=\"15920040\" target=\"_blank\">",
"        15920040",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gerstein HC, Yale JF, Harrist SB, et al, &ldquo;A Randomized Trial of Adding Insulin Glargine vs. Avoidance of Insulin in People with Type 2 Diabetes on Either No Oral Glucose-Lowering Agents or Submaximal Doses of Metformin and/or Sulphonylureas: The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study,&rdquo;",
"      <i>",
"       Diabet Med",
"      </i>",
"      , 2006, 23(7):736-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/36/3655/abstract-text/16842477/pubmed\" id=\"16842477\" target=\"_blank\">",
"        16842477",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Meneghini L, Koenen C, Rojas P, et al, &ldquo;Efficacy and Safety of Insulin Detemir in a Large Cohort of Patients With Type 2 Diabetes Using a Simplified Self-Adjusted Dosing Guideline -- Results of the Predictive 303 Study,&rdquo; Presented at: 67th Scientific Sessions of the American Diabetes Association; June 22-25, 2007; Chicago, IL.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nathan DM, Buse, JB, Davidson MB, et al, &ldquo;Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2009, 32(1):193-203.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/36/3655/abstract-text/18945920/pubmed\" id=\"18945920\" target=\"_blank\">",
"        18945920",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Qaseem A, Humphrey LL, Sweet DE, et al,&ldquo;Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2012, 156(3):218-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/36/3655/abstract-text/22312141/pubmed\" id=\"22312141\" target=\"_blank\">",
"        22312141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Riddle MC, Rosenstock J, Gerich J, et al, &ldquo;The Treat-to-Target Trial: Randomized Addition of Glargine or Human NPH Insulin to Oral Therapy of Type 2 Diabetic Patients,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2003, 26(11):3080-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/36/3655/abstract-text/14578243/pubmed\" id=\"14578243\" target=\"_blank\">",
"        14578243",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rodbard HW, Jellinger PS, Davidson JA, et al, &ldquo;Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control,&rdquo;",
"      <i>",
"       Endocr Pract",
"      </i>",
"      , 2009, 15(6):540-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/36/3655/abstract-text/19858063/pubmed\" id=\"19858063\" target=\"_blank\">",
"        19858063",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Silverstein J, Klingensmith G, Copeland K, et al, &ldquo;Care of Children and Adolescents With Type 1 Diabetes: A Statement of the American Diabetes Association,&rdquo;",
"      <i>",
"       Diabetes Care,",
"      </i>",
"      2005, 28(1):186-212.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/36/3655/abstract-text/15616254/pubmed\" id=\"15616254\" target=\"_blank\">",
"        15616254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9021 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-24A2ECD58B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_36_3655=[""].join("\n");
var outline_f3_36_3655=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2169301\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4782805\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2136162\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2136552\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2309882\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2136553\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8102569\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104231\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2343844\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2136554\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2136543\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2136514\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2136512\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2176662\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2138088\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2136517\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8102566\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6221026\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8102567\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2136515\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2137901\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2136516\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2137818\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8102570\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3422165\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8102687\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8102568\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038883\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2136544\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2136546\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9021\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9021|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?8/2/8229?source=related_link\">",
"      Insulin aspart protamine and insulin aspart: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/50/5926?source=related_link\">",
"      Insulin aspart protamine and insulin aspart: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_36_3656="Partial anomalous pulmonary venous connection";
var content_f3_36_3656=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Partial anomalous pulmonary venous connection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/36/3656/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/36/3656/contributors\">",
"     David R Fulton, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/36/3656/contributors\">",
"     Brian Soriano, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/36/3656/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/36/3656/contributors\">",
"     John K Triedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/36/3656/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/36/3656/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/36/3656/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Partial anomalous pulmonary venous connection (PAPVC) encompasses a specific group of congenital cardiovascular anomalies that are caused by the abnormal return of one or more, but not all, of the pulmonary veins directly to the right atrium or indirectly through a variety of venous connections from the anomalous pulmonary vein.",
"   </p>",
"   <p>",
"    The anatomic abnormalities that result in partial anomalous pulmonary connection (PAPVC), and the diagnosis and management of PAPVC will be reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall incidence of PAPVC is estimated to be 0.7 percent of the population [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3656/abstract/1\">",
"     1",
"    </a>",
"    ]. However, as this rate is based upon autopsy data, the true prevalence of PAPVC may actually be higher [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3656/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. Multiple case series report PAPVC as an incidental finding, which in most of these instances is asymptomatic.",
"   </p>",
"   <p>",
"    Although PAPVC can present as an isolated structural abnormality, it commonly occurs with other cardiac abnormalities, most often an atrial septal defect. In addition, patients with Turner syndrome are at an increased risk for PAPVC [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3656/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ANATOMIC VARIATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a wide range of pulmonary vein arrangements that return blood from the lung to the heart.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Normal variants return blood from the pulmonary circulation to the left atrium. The most common arrangement involves two left and two right pulmonary veins that form separate orifices and connect directly to the posterior wall of the left atrium. In the second most common variant, pulmonary veins from the entire right or left lung form a single confluent vessel before it connects into the left atrium, thereby forming a single orifice for an entire lung. In more uncommon cases, there can be five or more pulmonary vein connections, each draining a correspondingly smaller segment of lung but all connecting normally to the left atrium. Almost always, these variations in the number of normal connections have no clinical impact.",
"     </li>",
"     <li>",
"      Total anomalous pulmonary venous connection (TAPVC) occurs when all pulmonary veins from both lungs drain into the right atrium or into a venous channel in communication with the right atrium. There are four variants of TAPVs based upon the anatomical location of the anomalous connection: supracardiac (typically a vertical vein connecting to the innominate vein), cardiac (to the right atrium or coronary sinus), infracardiac (via the portal vein), or mixed connection(s) at two or more levels. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/51/10040?source=see_link\">",
"       \"Total anomalous pulmonary venous connection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Partial anomalous pulmonary venous connection (PAPVC) occurs when one or more, but not all, of the pulmonary veins return directly to the right atrium or indirectly through a variety of venous connections from a pulmonary vein to a systemic vein.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    PAPVC consists of two subtypes based upon their anatomy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3656/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Partial anomalous pulmonary venous connections",
"     </li>",
"     <li>",
"      Partial anomalous pulmonary venous drainage",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These variations are discussed in the next two sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Partial anomalous pulmonary venous connections",
"    </span>",
"    &nbsp;&mdash;&nbsp;In partial anomalous pulmonary venous connections (PAPVCs), the anomalous vein connects with a systemic vein resulting in the mixing of oxygenated blood from the pulmonary circulation with the systemic venous blood before returning to the right-side of the heart.",
"   </p>",
"   <p>",
"    The most common form of PAPVC is the left upper pulmonary vein that connects to the left innominate vein, which in turn drains into the superior vena cava (",
"    <a class=\"graphic graphic_movie graphicRef57752 \" href=\"UTD.htm?41/22/42338\">",
"     movie 1",
"    </a>",
"    ). In other cases, small segments of the right upper lobe connect directly to the superior vena cava, usually above the level of the azygous vein. Because of the location of the pulmonary vein connection, this anatomy is different from that of sinus venosus defects. Other more uncommon PAPVCs include anomalous pulmonary vein connections to the coronary sinus, azygous vein, or the inferior vena cava. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Sinus venosus defects'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In PAPVCs, a secundum atrial septal defect is typically present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Scimitar syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scimitar syndrome is a variant PAPVC, in which part or even the entire right lung is drained by right pulmonary veins that connect anomalously to the inferior vena cava (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51495 \" href=\"UTD.htm?32/31/33271\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef52567 \" href=\"UTD.htm?40/28/41411\">",
"     movie 2",
"    </a>",
"    ). The affected lung and its associated airways, which are drained by the scimitar vein, are often hypoplastic or have unusual bronchial or vascular distribution patterns. Sequestration as well as aortopulmonary collateral vessels may also involve the affected lung. Other cardiac defects are commonly seen and often include hypoplasia of the left heart or aorta [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3656/abstract/9\">",
"     9",
"    </a>",
"    ]. Left-sided scimitar syndrome has also been described, where some or all of the left pulmonary veins connect to the right-sided inferior vena cava [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3656/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A chest radiograph may show the shadow of these veins as they course and coalesce towards the diaphragm and the IVC, giving the characteristic \"scimitar\" appearance (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67663 \" href=\"UTD.htm?38/60/39874\">",
"     image 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Symptomatic infants with this diagnosis tend to present with more severe disease and have a poorer prognosis than patients who present as adults or children [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3656/abstract/9\">",
"     9",
"    </a>",
"    ]. At the time of diagnosis, most affected infants have pulmonary hypertension. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Presentation of scimitar syndrome'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Partial anomalous pulmonary venous drainage",
"    </span>",
"    &nbsp;&mdash;&nbsp;In partial anomalous pulmonary venous drainage (PAPVD), the pulmonary vein(s) connects normally and directly to the anatomic left atrium. However, due to other intracardiac defects (eg, sinus venosus defects), oxygenated blood from the anomalous vein can either enter only the right atrium or course both into the left and right atria. In either case, there is return of oxygenated blood to the right side of the heart, which mixes with the systemic venous blood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Sinus venosus defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normally, the right upper pulmonary vein courses behind the superior vena cava and part of the right atrium before connecting to the left atrium. A sinus venosus defect occurs when there is an absence or unroofing of the wall that normally separates the right upper pulmonary vein from the superior vena cava (",
"    <a class=\"graphic graphic_movie graphicRef73621 \" href=\"UTD.htm?6/22/6496\">",
"     movie 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef53750 \" href=\"UTD.htm?38/14/39151\">",
"     movie 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3656/abstract/11\">",
"     11",
"    </a>",
"    ]. This anomaly results in the right pulmonary vein draining into the superior vena cava, or in the right and left atrium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Malposition of the septum primum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anomalous drainage of one or more normally connecting pulmonary veins results from leftward malposition of the septum primum [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3656/abstract/12\">",
"     12",
"    </a>",
"    ]. In this condition, the posterior",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    superior attachments of the atrial septum primum are shifted so far leftward that the pulmonary veins from the right lung drain into the right atrium rather than to the left atrium. This anomaly is associated with heterotaxy syndrome and polysplenia [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3656/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;PAPVC results in recirculation of already oxygenated pulmonary venous blood through the pulmonary vasculature (left-to-right shunting). In patients with isolated PAPVC (no other associated cardiac anomaly), the magnitude of the shunt is dependent upon the proportion of anomalous draining blood compared to the total pulmonary venous return. This is usually dependent upon the following factors [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3656/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The number and size of anomalous pulmonary veins involved",
"     </li>",
"     <li>",
"      The pulmonary segment or lobes from which the anomalous veins originate because of differences in the distribution of blood flow to each lung",
"      <span class=\"nowrap\">",
"       segment/lobe",
"      </span>",
"     </li>",
"     <li>",
"      The relative resistance of the normal and abnormal pulmonary veins and the compliance of the respective receiving chambers [",
"      <a class=\"abstract\" href=\"UTD.htm?3/36/3656/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Significant shunting is associated with two or more anomalous connecting veins that may cause enlargement of the right atrium and ventricles, and dilation of the pulmonary artery. Patients with single pulmonary vein involvement are generally asymptomatic and do not have significant hemodynamic and cardiac structural changes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/15/4344?source=see_link\">",
"     \"Pathophysiology of left to right shunts\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The severity of clinical signs and symptoms is related to the degree of left-to-right shunting and the presence of other associated cardiac and pulmonary defects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Associated cardiac and pulmonary defects",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Atrial septal defect",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most patients with PAPVC, there is an associated cardiac defect, which is usually an atrial septal defect (ASD). In these patients, the clinical findings are similar to those seen in individuals with ASD and correspond to the degree of shunting from both the ASD and PAPVC.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a small degree of shunting are usually asymptomatic and are often identified incidentally by a murmur detected on physical examination.",
"     </li>",
"     <li>",
"      Although patients with moderate to large shunts may be asymptomatic in childhood, left-to-right shunting increases with age, and symptoms may appear generally during early adulthood before 40 years of age. Symptoms start with dyspnea and fatigue, and may progress to heart failure depending upon the degree of shunting. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26201?source=see_link&amp;anchor=H16#H16\">",
"       \"Classification and clinical features of isolated atrial septal defects in children\", section on 'Presentation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In symptomatic patients, the severity of findings is dependent upon the degree of shunting, and the presence of pulmonary hypertension or other cardiac anomalies. Clinical findings include dyspnea on exertion, recurrent pneumonia, and heart failure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Presentation of scimitar syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presentation of scimitar syndrome varies depending upon the age of diagnosis. Patients who present as infants have more severe symptoms related to heart failure and other cardiac and pulmonary conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3656/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Symptoms in infants with scimitar syndrome include tachypnea, poor feeding, failure to thrive, cyanosis, and lethargy.",
"   </p>",
"   <p>",
"    About one-half of older patients who are diagnosed after the first year of life remain asymptomatic and are typically identified by an incidental finding on chest radiograph. In other patients, there is a range of symptoms that includes fatigue, dyspnea, and recurrent pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3656/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other associated anomalies are common in patients with scimitar syndrome and include atrial septal defect, pulmonary sequestration, hypoplastic lung, dextrocardia, pulmonary vein stenosis, and other cardiac anomalies (eg, coarctation of the aorta, ventricular septal defect, and patent ductus arteriosus) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3656/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children with scimitar syndrome have a high rate of respiratory complications. In a study of 81 patients, 38 percent of the group had pulmonary infections and 43 percent reported wheezing episode during the last 12 months of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3656/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Isolated PAPVC",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with isolated PAPVC, no hemodynamic abnormality is generally noted unless 50 percent or more of the pulmonary blood flow is recirculated back to the pulmonary vasculature [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3656/abstract/17\">",
"     17",
"    </a>",
"    ]. Thus, individuals with a single anomalous pulmonary vein usually are asymptomatic and have a normal life span.",
"   </p>",
"   <p>",
"    In patients with isolated multiple pulmonary vein involvement, signs and symptoms are dependent upon the degree of left-to-right shunting and are similar to those with a uncomplicated atrial septal defect (ASD) or in cases of PAPVC that are associated with an ASD. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Atrial septal defect'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical findings are directly related to the degree of left-to-right shunting and are similar to those seen in patients with an atrial septal defect. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26201?source=see_link&amp;anchor=H17#H17\">",
"     \"Classification and clinical features of isolated atrial septal defects in children\", section on 'Physical examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following findings may be detected:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A precordial bulge due to atrial enlargement may be seen in patients with a large left-to-right shunt.",
"     </li>",
"     <li>",
"      The aortic and pulmonary components of S2 are generally fixed-split. In PAPVC without an atrial septal defect, the time interval between the aortic and pulmonary components may not be as prominent and can sometimes sound normal.",
"     </li>",
"     <li>",
"      A systolic ejection murmur is often heard along the left sternal border due to the increased amount of blood crossing the pulmonary valve in patients with moderate to large left-to-right shunting.",
"     </li>",
"     <li>",
"      A low-pitch diastolic rumble, representing flow across the tricuspid valve, may be heard at the left lower sternal border in patients with a large shunt.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H191012758\">",
"    <span class=\"h2\">",
"     Initial tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other tests that are usually performed in the evaluation for PAPVC include chest radiography and electrocardiogram. Although there may be findings that are suggestive of PAPVC, these are not diagnostic studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H191012765\">",
"    <span class=\"h3\">",
"     Chest radiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following radiographic findings are suggestive but not diagnostic of PAPVC:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiomegaly including right atrial prominence and right ventricular enlargement, which may be seen as retrosternal fullness on a lateral view, is suggestive of increased shunting.",
"     </li>",
"     <li>",
"      Increased pulmonary vascular markings provide evidence of significant left-to-right shunting.",
"     </li>",
"     <li>",
"      If the anomalous vein drains into the SVC or innominate vein, the superior mediastinal shadow may appear wide, or the SVC shadow prominent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In scimitar syndrome, the anomalous vein is often identifiable as it courses towards the diaphragm and the IVC, giving the characteristic \"scimitar\" appearance. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Scimitar syndrome'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial diagnosis of PAPVC may be made by echocardiography. The diagnosis is typically confirmed by magnetic resonance imaging (MRI), computed tomography (CT), or cardiac catheterization. Other tests, including chest radiography and electrocardiogram, may provide supportive evidence for the diagnosis of PAPVC but are not diagnostic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echocardiography is the most frequently used method for an initial diagnosis of PAPVC. PAPVC should be considered when the echocardiography demonstrates unexpected right atrial or ventricular enlargement, especially if there are no other explanations for the finding(s) (eg, secundum atrial septal defect). In cases with right heart enlargement, PAPVC is inferred if there are fewer than four pulmonary veins connecting to the left atrium, although one must consider the possibility of a single pulmonary vein draining an entire lung.",
"   </p>",
"   <p>",
"    In addition, PAPVC should be considered if the superior vena cava, innominate vein, or inferior vena cava appears dilated, and no other clear explanations are present. In these cases the anomalous pulmonary vein may connect directly to these structures.",
"   </p>",
"   <p>",
"    Color flow mapping and other Doppler techniques may aid the identification of anomalous connections to the innominate vein, superior and inferior vena cavas, or right atrium (",
"    <a class=\"graphic graphic_movie graphicRef73621 \" href=\"UTD.htm?6/22/6496\">",
"     movie 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3656/abstract/18\">",
"     18",
"    </a>",
"    ]. Transesophageal echocardiography (TEE) is more sensitive than transthoracic echocardiography (TTE) in detecting PAPVC (",
"    <a class=\"graphic graphic_movie graphicRef73621 \" href=\"UTD.htm?6/22/6496\">",
"     movie 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef53750 \" href=\"UTD.htm?38/14/39151\">",
"     movie 4",
"    </a>",
"    ) and heart chamber enlargement [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3656/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. TEE is not usually employed to evaluate the superior-most aspect of the superior vena cava or innominate veins; these structures are better evaluated using TTE.",
"   </p>",
"   <p>",
"    A potential limitation of echocardiography is the availability of acoustic windows. Vessels that cross behind large airways such as the mainstem bronchi are masked due to attenuation of the ultrasound beams. In some patients, especially those with chronic lung disease, the anterior and medial margins of the lungs can mask the areas of interest. Distinguishing between a secundum atrial septal defect and a sinus venosus defect, with or without anomalous pulmonary vein connections, is sometimes challenging. While TEE can circumvent some of the issues with poor acoustic windows, it also can be subject to the same problems when the airways obscure areas of interest as TTE.",
"   </p>",
"   <p>",
"    Prenatal diagnosis of PAPVC by fetal echocardiography is feasible and has been reported in a large tertiary care center [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3656/abstract/21,22\">",
"     21,22",
"    </a>",
"    ], although its predictive value remains to be fully defined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) has become widely available as a diagnostic technique for cardiovascular imaging. It is now customary to use the term cardiovascular magnetic resonance (CMR) when referring to MRI of the heart and blood vessels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=see_link\">",
"     \"Clinical utility of cardiovascular magnetic resonance imaging\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cardiac MRI has increasingly been used to diagnose and characterize congenital heart disease, including PAPVC [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3656/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. It can provide additional information, including quantitation of heart chamber volumes, ventricular mass, and blood flow through the great vessels when other modalities, such as echocardiography, yield equivocal findings [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3656/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are several techniques used in cardiac MRI including the following, which are particularly useful in the diagnosis of PAPVC.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MR angiography (MRA) using gadolinium-based intravenous contrast agents provides enhanced visualization of the pulmonary vasculature including the anomalous pulmonary vein(s) (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef51495 \" href=\"UTD.htm?32/31/33271\">",
"       image 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Phase velocity mapping, a variant of gradient echo, is another technique that is used to directly measure blood flow. It can measure the ratio of pulmonary to systemic blood flow noninvasively, also known as shunt volume or Qp:Qs [",
"      <a class=\"abstract\" href=\"UTD.htm?3/36/3656/abstract/27,28\">",
"       27,28",
"      </a>",
"      ]. In patients with PAPVC, this ratio increases with the degree of left-to-right shunting.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The optimal use of CMR is in cooperative patients, as ideal images are obtained in patients who are able to hold their breath. CMR imaging in young children or anxious patients often requires conscious sedation or even general anesthesia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=see_link\">",
"     \"Procedural sedation in children outside of the operating room\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac computed tomography (CCT) can be used to confirm PAPVC [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3656/abstract/29\">",
"     29",
"    </a>",
"    ]. CCT has several advantages over other diagnostic modalities. It provides more detailed anatomic information than echocardiography, and like CMR, is not limited by narrow acoustic windows. CCT is more readily available than cardiac magnetic resonance imaging (CMR). It can be performed in a shorter period of time than CMR and, as a result, may eliminate the need for anesthesia or sedation in younger patients. If necessary, contrast can be given after non-contrast images have been obtained to provide additional anatomic detail including enhanced visualization of the pulmonary vasculature. However, the benefits of CCT must be balanced with the known long-term risks of ionizing radiation especially in small children [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3656/abstract/30-32\">",
"     30-32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Cardiac catheterization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although cardiac catheterization can be a definitive diagnostic procedure, it is increasingly performed as a therapeutic intervention to occlude small anomalous connections rather than for diagnosis because of the availability of other diagnostic modalities (ie, echocardiography, magnetic resonance imaging, and computed tomography) in patients with PAPVC. Cardiac catheterization also provides hemodynamic information, such as pulmonary vascular resistance, cardiac output, and ventricular pressures. Shunt volume can be calculated by oximetry, but some authors have questioned its reliability in PAPVC [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3656/abstract/33\">",
"     33",
"    </a>",
"    ], since mixed venous saturation can be difficult to measure, especially if the anomalous vein drains directly into the superior vena cava.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Electrocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with PAPVC, the electrocardiogram may demonstrate evidence of right heart enlargement. These changes may include right axis deviation of the frontal plane QRS complex, and evidence of right atrial hypertrophy with an increased amplitude of the P wave (",
"    <a class=\"graphic graphic_waveform graphicRef78126 \" href=\"UTD.htm?22/59/23472\">",
"     waveform 1",
"    </a>",
"    )",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    right ventricular hypertrophy with tall R waves in the right precordial leads (V1 and V2), and deep S waves in the left precordial leads (V5 and V6) (",
"    <a class=\"graphic graphic_waveform graphicRef63763 \" href=\"UTD.htm?41/46/42730\">",
"     waveform 2",
"    </a>",
"    ). In patients with sinus venosus defects, the p-wave axis may be deviated leftward with a negative p-wave in lead III [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3656/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27204?source=see_link\">",
"     \"ECG tutorial: Chamber enlargement and hypertrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, a normal electrocardiogram may also be present in patients with PAPVC. As a result, electrocardiogram is not helpful in excluding this diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery is the definitive treatment in PAPVC. However, asymptomatic patients with PAPVC with small left-to-right shunt do not require intervention, as the defect has no significant clinical impact, and they have a normal life expectancy without correction [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3656/abstract/13,17\">",
"     13,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Depending on the size of the patient and the location of the anomalous connection, surgical correction can be difficult to perform. Therefore, the likelihood of a successful procedure and its potential benefit must be weighed against the risks of the intervention.",
"   </p>",
"   <p>",
"    Surgical treatment is considered in the following circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3656/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A hemodynamically significant left-to-right shunt (a ratio of pulmonary to systemic blood flow is greater than 2:1) often manifested as right ventricular volume overload.",
"     </li>",
"     <li>",
"      Recurrent pulmonary infections, particularly with scimitar syndrome and pulmonary sequestration.",
"     </li>",
"     <li>",
"      Compression or obstruction of surrounding structures caused by the anomalous vein. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/5/27735?source=see_link\">",
"       \"Vascular rings\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      During surgical repair of other major cardiac lesions depending upon the surgical risk of repair and level and degree of shunting.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The surgical procedure and technique vary and are dependent upon the anatomy and the presence of other associated cardiac anomalies. Transcatheter occlusion also may be used to reduce the shunting of PAPVC in selected cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The outcome depends upon the underlying anatomy and the presence of associated conditions such as pulmonary hypertension, sequestration, or hypoplasia.",
"   </p>",
"   <p>",
"    Patients with scimitar syndrome who present as infants have historically had poor outcome with significant morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3656/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. However, over the past decade, surgical outcome has improved. This was illustrated in a case series of 68 patients (mean age at surgery 1.4 years) with a mean follow-up of 4.8 years [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3656/abstract/35\">",
"     35",
"    </a>",
"    ]. There were six deaths (9 percent) including two late deaths due to severe pulmonary arterial hypertension. Four patients required intervention for restenosis, and the remainder were asymptomatic at follow-up without evidence of scimitar drainage stenosis.",
"   </p>",
"   <p>",
"    Patients with other causes of PAPVC generally have an excellent outcome including those who undergo surgical correction [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3656/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. In a case series of 306 children who underwent surgery for PAPVC, follow-up at 15 years demonstrated no deaths and limited significant morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3656/abstract/36\">",
"     36",
"    </a>",
"    ]. In this cohort, scimitar vein stenosis did not occur in 85 percent of patients at ten-year follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Partial anomalous pulmonary venous connection (PAPVC) encompasses a specific group of congenital cardiac anomalies that are caused by the abnormal return of one or more, but not all, of the pulmonary veins to the right side of the heart. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Anatomic variations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PAPVC results in recirculation of pulmonary venous blood through the pulmonary vasculature (left-to-right shunting). The amount of shunted pulmonary blood flow is dependent upon the number and size of anomalous pulmonary veins involved. Significant shunting is associated with two or more anomalous connecting veins, which may result in enlargement of the right atrium and ventricle, and dilation of the pulmonary artery. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Physiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical presentation of PAPVC is related to the degree of left-to-right shunting and the presence of other associated cardiac and pulmonary defects. Atrial septal defect (ASD) is present in most patients with PAPVC. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients with a small degree of shunting either with isolated PAPVC or a small ASD are generally asymptomatic and are identified incidentally by echocardiography performed for other indications.",
"     </li>",
"     <li>",
"      Patients with greater degrees of shunting may present with dyspnea and fatigue that may progress to heart failure as left-to-right shunting increases with age.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Scimitar syndrome is a variant PAPVC, in which part or even the entire right lung is drained by right pulmonary veins that connect anomalously to the inferior vena cava (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef51495 \" href=\"UTD.htm?32/31/33271\">",
"       image 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_movie graphicRef52567 \" href=\"UTD.htm?40/28/41411\">",
"       movie 2",
"      </a>",
"      ). Infants who present with this syndrome have more severe diseases (heart failure, recurrent pulmonary infections, pulmonary hypertension, and pulmonary and cardiac anomalies) than patients who present after one year of life. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Scimitar syndrome'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Presentation of scimitar syndrome'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial diagnosis of PAPVC may be made by echocardiography. The diagnosis is typically confirmed by magnetic resonance imaging, computed tomography, or cardiac catheterization. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgery is the definitive treatment. However, asymptomatic patients with PAPVC and small left-to-right shunt do not require intervention, as the defect has no significant clinical impact, and they have a normal life expectancy. The benefit of surgical intervention must be weighed against the risk of the procedure. The surgical procedure varies and is dependent upon the involved anatomy and the presence of other associated cardiac anomalies. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      With the exception of infants with scimitar syndrome, the outcome for patients with PAPVC generally is excellent including those who undergo surgical correction. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3656/abstract/1\">",
"      HEALEY JE Jr. An anatomic survey of anomalous pulmonary veins: their clinical significance. J Thorac Surg 1952; 23:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3656/abstract/2\">",
"      Garduno C, Chew S, Forbess J, et al. Persistent left superior vena cava and partial anomalous pulmonary venous connection: incidental diagnosis by transesophageal echocardiography during coronary artery bypass surgery. J Am Soc Echocardiogr 1999; 12:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3656/abstract/3\">",
"      Miwa K, Takamori S, Hayashi A, et al. Incidental partial anomalous pulmonary venous connection in left lung cancer. Jpn J Thorac Cardiovasc Surg 2004; 52:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3656/abstract/4\">",
"      Sasaki H, Naka N, Kitahara N, et al. Right partial anomalous pulmonary venous connection found during lobectomy for coexisting lung cancer and tuberculosis: report of a case. Clin Lung Cancer 2006; 7:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3656/abstract/5\">",
"      Sobrinho G, Salcher J. Partial anomalous pulmonary vein drainage of the left lower lobe: incidental diagnostic after central venous cannulation. Crit Care Med 2003; 31:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3656/abstract/6\">",
"      Bechtold SM, Dalla Pozza R, Becker A, et al. Partial anomalous pulmonary vein connection: an underestimated cardiovascular defect in Ullrich-Turner syndrome. Eur J Pediatr 2004; 163:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3656/abstract/7\">",
"      Ho VB, Bakalov VK, Cooley M, et al. Major vascular anomalies in Turner syndrome: prevalence and magnetic resonance angiographic features. Circulation 2004; 110:1694.",
"     </a>",
"    </li>",
"    <li>",
"     Geva, T, Van Praagh, S. Anomalies of the Pulmonary Veins. In: Moss and Adams' Heart Disease in Infants, Children, and Adolescents: Including the Fetus and Young Adult, 7th ed, Lippincott Williams and Wilkins, Philadelphia, PA 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3656/abstract/9\">",
"      Gao YA, Burrows PE, Benson LN, et al. Scimitar syndrome in infancy. J Am Coll Cardiol 1993; 22:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3656/abstract/10\">",
"      Juraszek AL, Cohn H, Van Praagh R, Van Praagh S. Isolated left-sided scimitar vein connecting all left pulmonary veins to the right inferior vena cava. Pediatr Cardiol 2005; 26:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3656/abstract/11\">",
"      Van Praagh S, Carrera ME, Sanders SP, et al. Sinus venosus defects: unroofing of the right pulmonary veins--anatomic and echocardiographic findings and surgical treatment. Am Heart J 1994; 128:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3656/abstract/12\">",
"      Van Praagh S, Carrera ME, Sanders S, et al. Partial or total direct pulmonary venous drainage to right atrium due to malposition of septum primum. Anatomic and echocardiographic findings and surgical treatment: a study based on 36 cases. Chest 1995; 107:1488.",
"     </a>",
"    </li>",
"    <li>",
"     Ward KE, Mullins CE. Anomalous pulmonary venous connections, pulmonary vein stenosis, and atresia of the common pulmonary vein. In: The Science and Practice of Pediatric Cardiology, Garson A Jr, Bricker JT, Fisher DJ, Neish SR (Eds), Williams and Wilkins, Baltimore 1998. p.1431.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3656/abstract/14\">",
"      Najm HK, Williams WG, Coles JG, et al. Scimitar syndrome: twenty years' experience and results of repair. J Thorac Cardiovasc Surg 1996; 112:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3656/abstract/15\">",
"      Huddleston CB, Exil V, Canter CE, Mendeloff EN. Scimitar syndrome presenting in infancy. Ann Thorac Surg 1999; 67:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3656/abstract/16\">",
"      Chemin A, Bonnet D, Le Bourgeois M, et al. Respiratory outcome in children with scimitar syndrome. J Pediatr 2013; 162:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3656/abstract/17\">",
"      Brody, H. Drainage of the pulmonary veins into the right-side of the heart. Arch Pathol 1942;33:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3656/abstract/18\">",
"      Al-Ahmari S, Chandrasekaran K, Brilakas E, et al. Isolated partial anomalous pulmonary venous connection: Diagnostic value of suprasternal color flow imaging and contrast echocardiography. J Am Soc Echocardiogr 2003; 16:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3656/abstract/19\">",
"      St&uuml;mper O, Vargas-Barron J, Rijlaarsdam M, et al. Assessment of anomalous systemic and pulmonary venous connections by transoesophageal echocardiography in infants and children. Br Heart J 1991; 66:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3656/abstract/20\">",
"      Ammash NM, Seward JB, Warnes CA, et al. Partial anomalous pulmonary venous connection: diagnosis by transesophageal echocardiography. J Am Coll Cardiol 1997; 29:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3656/abstract/21\">",
"      Valsangiacomo ER, Hornberger LK, Barrea C, et al. Partial and total anomalous pulmonary venous connection in the fetus: two-dimensional and Doppler echocardiographic findings. Ultrasound Obstet Gynecol 2003; 22:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3656/abstract/22\">",
"      Pascoe RD, Oh JK, Warnes CA, et al. Diagnosis of sinus venosus atrial septal defect with transesophageal echocardiography. Circulation 1996; 94:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3656/abstract/23\">",
"      Festa P, Ait-Ali L, Cerillo AG, et al. Magnetic resonance imaging is the diagnostic tool of choice in the preoperative evaluation of patients with partial anomalous pulmonary venous return. Int J Cardiovasc Imaging 2006; 22:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3656/abstract/24\">",
"      Prasad SK, Soukias N, Hornung T, et al. Role of magnetic resonance angiography in the diagnosis of major aortopulmonary collateral arteries and partial anomalous pulmonary venous drainage. Circulation 2004; 109:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3656/abstract/25\">",
"      Ferrari VA, Scott CH, Holland GA, et al. Ultrafast three-dimensional contrast-enhanced magnetic resonance angiography and imaging in the diagnosis of partial anomalous pulmonary venous drainage. J Am Coll Cardiol 2001; 37:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3656/abstract/26\">",
"      Riesenkampff EM, Schmitt B, Schnackenburg B, et al. Partial anomalous pulmonary venous drainage in young pediatric patients: the role of magnetic resonance imaging. Pediatr Cardiol 2009; 30:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3656/abstract/27\">",
"      Hundley WG, Li HF, Lange RA, et al. Assessment of left-to-right intracardiac shunting by velocity-encoded, phase-difference magnetic resonance imaging. A comparison with oximetric and indicator dilution techniques. Circulation 1995; 91:2955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3656/abstract/28\">",
"      Powell AJ, Tsai-Goodman B, Prakash A, et al. Comparison between phase-velocity cine magnetic resonance imaging and invasive oximetry for quantification of atrial shunts. Am J Cardiol 2003; 91:1523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3656/abstract/29\">",
"      Otsuka M, Itoh A, Haze K. Sinus venosus type of atrial septal defect with partial anomalous pulmonary venous return evaluated by multislice CT. Heart 2004; 90:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3656/abstract/30\">",
"      Brenner D, Elliston C, Hall E, Berdon W. Estimated risks of radiation-induced fatal cancer from pediatric CT. AJR Am J Roentgenol 2001; 176:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3656/abstract/31\">",
"      Huda W. Radiation doses and risks in chest computed tomography examinations. Proc Am Thorac Soc 2007; 4:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3656/abstract/32\">",
"      Brenner DJ, Hall EJ. Computed tomography--an increasing source of radiation exposure. N Engl J Med 2007; 357:2277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3656/abstract/33\">",
"      Dyme JL, Prakash A, Printz BF, et al. Physiology of isolated anomalous pulmonary venous connection of a single pulmonary vein as determined by cardiac magnetic resonance imaging. Am J Cardiol 2006; 98:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3656/abstract/34\">",
"      Davia JE, Cheitlin MD, Bedynek JL. Sinus venosus atrial septal defect: analysis of fifty cases. Am Heart J 1973; 85:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3656/abstract/35\">",
"      Vida VL, Padalino MA, Boccuzzo G, et al. Scimitar syndrome: a European Congenital Heart Surgeons Association (ECHSA) multicentric study. Circulation 2010; 122:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3656/abstract/36\">",
"      Alsoufi B, Cai S, Van Arsdell GS, et al. Outcomes after surgical treatment of children with partial anomalous pulmonary venous connection. Ann Thorac Surg 2007; 84:2020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3656/abstract/37\">",
"      Weiman DS, Lee K, Levett JM, Replogle RL. Partial anomalous pulmonary venous return: a ten-year experience. Tex Heart Inst J 1985; 12:239.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5764 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-259ED97FEC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_36_3656=[""].join("\n");
var outline_f3_36_3656=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ANATOMIC VARIATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Partial anomalous pulmonary venous connections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Scimitar syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Partial anomalous pulmonary venous drainage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Sinus venosus defects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Malposition of the septum primum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Associated cardiac and pulmonary defects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Atrial septal defect",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Presentation of scimitar syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Isolated PAPVC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H191012758\">",
"      Initial tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H191012765\">",
"      - Chest radiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Computed tomography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Cardiac catheterization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5764\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5764|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?32/31/33271\" title=\"diagnostic image 1\">",
"      Scimitar syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?38/60/39874\" title=\"diagnostic image 2\">",
"      CXR MRI scimitar syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5764|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?41/22/42338\" title=\"movie 1\">",
"      Partial anomalous pulmonary venous connection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?40/28/41411\" title=\"movie 2\">",
"      Cardiac cath scimitar syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?6/22/6496\" title=\"movie 3\">",
"      TEE sinus venosus defect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?38/14/39151\" title=\"movie 4\">",
"      TTE sinus venosus defect",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5764|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?22/59/23472\" title=\"waveform 1\">",
"      RA enlargement ECG tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?41/46/42730\" title=\"waveform 2\">",
"      RVH tutorial",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26201?source=related_link\">",
"      Classification and clinical features of isolated atrial septal defects in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=related_link\">",
"      Clinical utility of cardiovascular magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27204?source=related_link\">",
"      ECG tutorial: Chamber enlargement and hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/15/4344?source=related_link\">",
"      Pathophysiology of left to right shunts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=related_link\">",
"      Procedural sedation in children outside of the operating room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/51/10040?source=related_link\">",
"      Total anomalous pulmonary venous connection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/5/27735?source=related_link\">",
"      Vascular rings",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_36_3657="Obstetric anesthetic management of women with acquired or congenital heart disease";
var content_f3_36_3657=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Obstetric anesthetic management of women with acquired or congenital heart disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/36/3657/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/36/3657/contributors\">",
"     Katherine W Arendt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/36/3657/contributors\">",
"     Carl H Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/36/3657/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/36/3657/contributors\">",
"     David L Hepner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/36/3657/contributors\">",
"     Susan M Ramin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/36/3657/contributors\">",
"     Heidi M Connolly, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/36/3657/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/36/3657/contributors\">",
"     Kari G Doucette, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/36/3657/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical management of the pregnant woman with acquired heart disease (AHD) or congenital heart disease (CHD) requires an understanding of her cardiac anatomy and physiology; the physiologic changes associated with pregnancy, labor, and delivery; the hemodynamic alterations induced by different analgesic and anesthetic techniques; and how these factors affect one another. This is best achieved by a multidisciplinary team of providers (cardiologists, obstetricians, and anesthesiologists) who together develop an individualized management plan for each patient [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3657/abstract/1\">",
"     1",
"    </a>",
"    ]. The importance of antepartum preparation and communication cannot be overstated, given that obstetric and cardiac complications may require rapid intervention.",
"   </p>",
"   <p>",
"    This topic will discuss obstetric anesthetic management of women with heart disease. A general discussion of pregnancy in AHD and CHD, as well as considerations relating to specific CHD lesions in pregnant women, can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29097?source=see_link\">",
"     \"Acquired heart disease and pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29818?source=see_link\">",
"     \"Pregnancy in women with congenital heart disease: General principles\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/21/35159?source=see_link\">",
"     \"Pregnancy in women with congenital heart disease: Specific lesions\"",
"    </a>",
"    .) The management of heart failure during pregnancy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/34/1577?source=see_link\">",
"     \"Management of heart failure in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HEMODYNAMIC CHANGES DURING PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular adaptations to normal pregnancy are summarized in the figures (",
"    <a class=\"graphic graphic_figure graphicRef54685 graphicRef61948 graphicRef55985 \" href=\"UTD.htm?20/30/20963\">",
"     figure 1A-C",
"    </a>",
"    ) and discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20105?source=see_link\">",
"     \"Maternal cardiovascular and hemodynamic adaptations to pregnancy\"",
"    </a>",
"    .) An understanding of these hemodynamic changes of pregnancy allows the clinician to anticipate which cardiac conditions are likely to decompensate antepartum and peripartum. As an example, women with stenotic valvular lesions are typically at higher risk of pregnancy-related heart failure than those with regurgitant valvular lesions. The physiology of aortic stenosis requires adequate afterload for coronary perfusion to supply the thickened myocardium, whereas mitral stenosis physiology gains no benefit from decreased afterload. In aortic insufficiency, however, the decreased afterload lessens the regurgitant volume improving hemodynamics. Likewise, in mitral insufficiency, the lesser systemic pressure may reduce the degree of valvular regurgitation and improve functional cardiac output.",
"   </p>",
"   <p>",
"    The following synopses describe hemodynamic changes in normal pregnancy and selected pregnancy complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Antepartum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant hemodynamic changes begin as early as the fourth week of gestation and persist for several months postpartum. Systemic vascular tone falls, inducing a compensatory 30 percent increase in cardiac output by the end of the first trimester. Cardiac output plateaus around week 26 at a level about 40 percent above its prepregnancy baseline, and then gradually falls by about 10 percent until by term it is about 30 percent above baseline. Both systolic and diastolic blood pressure decrease (by about 10 mmHg and 5 mmHg, respectively) until 30 weeks of gestation due to decreased vascular tone. Maternal heart rate increases (by about 15 beats per minute), peripheral and pulmonary vascular resistance decrease, colloid osmotic pressure decreases, and a dilutional anemia occurs (due to a disproportionate increase in red cell volume [1500 mL to 1800 mL] compared to plasma volume [2500 mL to 3800 mL]).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Intrapartum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac output increases progressively during the first stage of labor, sometimes reaching an additional 50 percent by the late second stage. Immediately postpartum, autotransfusion of uteroplacental blood to the intravascular space significantly increases cardiac output; within the first 10 minutes following a term vaginal delivery, the cardiac output and stroke volume increase by 59 and 71 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3657/abstract/2\">",
"     2",
"    </a>",
"    ]. At one hour postpartum, both the cardiac output and stroke volume remain increased (by 49 and 67 percent, respectively) while the heart rate decreases by 15 percent; blood pressure remains relatively unchanged [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3657/abstract/3\">",
"     3",
"    </a>",
"    ]. These hemodynamic changes resolve slowly over the ensuing weeks, with typical return to nongravid status by six months postpartum [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3657/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Cesarean delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;During cesarean delivery, if neuraxial anesthesia is performed, initial hypotension",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bradycardia can result from the local anesthetic-induced sympathectomy. This is typically treated with bolus intravenous hydration and vasopressor therapy, if required. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/2/39977?source=see_link\">",
"     \"Anesthesia for cesarean delivery\"",
"    </a>",
"    .) At the time of cesarean delivery, cardiac index increases by 47 percent, stroke volume index decreases by 39 percent and mean arterial pressure remains stable. These acute changes occur within two minutes of delivery of the fetus and persist for about 10 minutes postpartum [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3657/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Multiple gestation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with multiple gestations, maternal blood volume expansion occurs earlier in gestation and reaches a peak volume that is 40 percent greater than in singleton gestations. Anemia can be more profound and blood loss at delivery is typically greater, and can be twice that associated with a singleton birth [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3657/abstract/6\">",
"     6",
"    </a>",
"    ]. Venous thromboembolism, pulmonary edema, gestational hypertension and preeclampsia also occur more frequently.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Preeclampsia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac patients with preeclampsia and eclampsia are exquisitely sensitive to sympathetic stimulation due to impaired endothelial function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=see_link\">",
"     \"Preeclampsia: Clinical features and diagnosis\"",
"    </a>",
"    .) Cerebral vascular accidents from malignant hypertension must be avoided with adequate antihypertensive therapy, a deep induction prior to laryngoscopy, adequate anesthesia throughout surgery, and careful titration of sympathomimetic agents. These patients can also exhibit abnormal coagulation studies, which can complicate or preclude regional anesthesia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/26/17832?source=see_link\">",
"     \"Abnormalities of coagulation and platelet function in preeclampsia\"",
"    </a>",
"    .) This complex disease state and its clinical implications are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21882?source=see_link\">",
"     \"Preeclampsia: Management and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/2/32808?source=see_link\">",
"     \"Expectant management of severe preeclampsia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     RISK STRATIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk stratification helps in planning the appropriate monitoring, intravascular access, and anesthetic techniques that will provide the safest possible delivery for the mother and baby. An individualized management plan must be formulated for each patient since each patient's cardiac risks are unique. In practice, anesthesiologists do not follow one specific risk stratification system as a formula for management. Instead, understanding these indices assists the anesthesiologist in constructing an impression of the gravity of the patient's condition. Then, by combining the predicted physiologic consequences associated with the patient's cardiac lesion, the physiologic changes associated with pregnancy, labor, and delivery, and the hemodynamic alterations induced by different analgesic and anesthetic techniques, an anesthetic plan for delivery can be formulated.",
"   </p>",
"   <p>",
"    Multiple risk stratification systems have also been published [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3657/abstract/7-13\">",
"     7-13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Cardiac Disease in Pregnancy (CARPREG) investigators identified predictors of primary cardiac events during pregnancy and postpartum [",
"      <a class=\"abstract\" href=\"UTD.htm?3/36/3657/abstract/7,8,12\">",
"       7,8,12",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29818?source=see_link&amp;anchor=H11#H11\">",
"       \"Pregnancy in women with congenital heart disease: General principles\", section on 'CARPREG risk index'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Another group combined data on the pregnancies of women with AHD or CHD and stratified cardiac lesions according to their risk of death or severe morbidity during pregnancy (",
"      <a class=\"graphic graphic_table graphicRef74878 \" href=\"UTD.htm?32/48/33548\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/36/3657/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The American College of",
"      <span class=\"nowrap\">",
"       Cardiology/American",
"      </span>",
"      Heart Association",
"      <span class=\"nowrap\">",
"       (ACC/AHA)",
"      </span>",
"      and the European Society of Cardiology (ESC) guidelines on the management of valvular heart disease consider women with one of the following valve lesions to be at high maternal",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fetal risk during pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?3/36/3657/abstract/10,11\">",
"       10,11",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Severe aortic stenosis with or without symptoms",
"     </li>",
"     <li>",
"      Symptomatic mitral stenosis (NYHA class II to IV)",
"     </li>",
"     <li>",
"      Aortic or mitral regurgitation with NYHA class III to IV symptoms",
"     </li>",
"     <li>",
"      Aortic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      mitral valve disease with severe left ventricular dysfunction (defined as a left ventricular ejection fraction less than 40 percent) or severe pulmonary hypertension (defined as pulmonary artery pressure &gt;75 percent of systemic pressure)",
"     </li>",
"     <li>",
"      Marfan syndrome with or without aortic regurgitation",
"     </li>",
"     <li>",
"      Mechanical prosthetic valve requiring anticoagulation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29818?source=see_link&amp;anchor=H12#H12\">",
"     \"Pregnancy in women with congenital heart disease: General principles\", section on 'Major society guidelines'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     OBSTETRICAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with cardiac disease that are considered to be at high maternal or fetal risk should receive prenatal care and deliver at a tertiary care center [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3657/abstract/1,14\">",
"     1,14",
"    </a>",
"    ]. The health care team should have a thorough understanding of the management of potential complications of AHD and CHD in the intrapartum and peripartum periods, and the tertiary center should have appropriate facilities for evaluation, monitoring, and treatment of potential complications of heart disease. If possible, delivery should be planned (scheduled induction or cesarean delivery) to enable all members of the healthcare team to be present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Indications for cesarean delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cesarean delivery is rarely performed solely for a maternal cardiac indication. Exceptions include aortopathy with a dilated root &gt;4 cm or progressive aortic enlargement noted with advancing gestation, aortic dissection or aortic aneurysm, severe pulmonary hypertension, or Eisenmenger syndrome, because intrapartum increases in cardiac output related to contractions may significantly increase the risk of a cardiac event (",
"    <a class=\"graphic graphic_figure graphicRef79834 graphicRef69056 \" href=\"UTD.htm?35/8/35975\">",
"     figure 2A-B",
"    </a>",
"    ). Maternal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    treatment within two weeks of delivery is another possible indication for cesarean delivery because of risk of transplacental anticoagulation leading to fetal intracranial hemorrhage during vaginal birth. Finally, if a facility does not have the capabilities to simultaneously perform required cardiac monitoring and labor management (particularly if invasive hemodynamic monitoring is required), a planned elective cesarean delivery may be the safest option. For example, the decision as to route of delivery in women with heart failure or critical valvular stenosis should be individualized depending on available facilities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Vaginal delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no consensus regarding absolute contraindications to vaginal delivery, as this decision is usually contingent on maternal status at time of delivery, her anticipated cardiopulmonary tolerance to the increased hemodynamic demands of labor, and concurrent fetal condition. Given the inherent unpredictability of delivery timing with either spontaneous or induced labor, care should be taken to confirm availability of all necessary support personnel throughout the labor process.",
"   </p>",
"   <p>",
"    The typical management of labor and delivery should be modified to accommodate the hemodynamic limitations of the patient with heart disease. A left lateral decubitus position will enhance venous return, and supplemental oxygen should be given if pulse oximetry indicates decreased oxygenation. A dense epidural anesthetic early in labor can be used to allow the patient to labor comfortably, since pain and anxiety have multiple potentially deleterious hemodynamic effects (see",
"    <a class=\"local\" href=\"#H14\">",
"     'Labor analgesia'",
"    </a>",
"    below). The epidural anesthetic must provide deep sacral coverage so the mother does not feel either pain or a strong reflexive urge to push.",
"   </p>",
"   <p>",
"    If desired, fetal descent during the majority of the second stage can be accomplished exclusively by uterine contractions without the aid of maternal expulsive efforts. When the fetal head reaches the pelvic floor, a low or outlet operative vaginal delivery (either forceps or vacuum extraction) can be performed to avoid the physiologic changes associated with maternal Valsalva maneuvers (pushing): increased intrathoracic pressure &mdash;&gt; decreased venous return &mdash;&gt; decreased preload &mdash;&gt; decreased cardiac output. In our series of 15 women with surgically repaired tetralogy of Fallot who underwent vaginal delivery (assisted or unassisted) with neuraxial analgesia, 11 (73 percent) had a passive second stage with minimal or no pushing [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3657/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether the maternal and fetal risks of operative vaginal delivery outweigh the maternal cardiac risk associated with Valsalva maneuvers is debatable and should probably be individualized for each patient. While most obstetricians would likely not permit a prolonged second stage of labor in a patient with a dilated aortic root, a patient with well-compensated moderate aortic stenosis may remain asymptomatic despite repeated Valsalva maneuvers. In fact, in one study, operative vaginal delivery following a passive second stage appeared to increase the risk of maternal postpartum hemorrhage, as well as third and fourth degree perineal laceration [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3657/abstract/16\">",
"     16",
"    </a>",
"    ]. Because of these maternal risks, along with the fetal risks inherent in surgical vaginal delivery, it seems reasonable to attempt a trial of Valsalva maneuver in the second stage for most parturients with heart disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/39/15994?source=see_link\">",
"     \"Operative vaginal delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Induction of labor, if required, is usually performed in a conventional manner. Particular attention to volume status is important if",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    infusion is prolonged. If cervical ripening is performed,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    or mechanical methods, including balloon catheter or cervical dilators (laminaria), are effective. Cardiovascular side effects of misoprostol are rare. With mechanical methods, vagal stimulation with consequent maternal bradycardia can occur if there is forcible cervical dilation. Amniotomy is an option for patients with favorable cervical status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ANESTHETIC MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Preoperative evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The obstetric anesthesiology team should obtain a thorough cardiac, obstetric, medical, and anesthetic history; consultation should occur well in advance of delivery if possible. In particular, it is important to ascertain for the presence of intracardiac shunting, cyanosis, prior arrhythmias, current pacemaker, left heart obstruction, poor functional status, prior episodes of heart failure, and left and right heart function. Documentation of the patient's acquired or congenital heart lesion and all palliative or reparative procedures should be reviewed. Any pertinent recent cardiac testing, including echocardiograms, should be reviewed.",
"   </p>",
"   <p>",
"    The managing obstetrician should discuss with the anesthesiologist the likelihood of successful vaginal versus cesarean delivery and potential complications. Factors such as abnormal placentation, multiple prior cesarean deliveries, or prior postpartum hemorrhage may prompt additional intravascular access, while multiple gestation or preeclampsia may prompt more judicious use of fluids.",
"   </p>",
"   <p>",
"    Although the majority of pregnant women with congenital heart disease have favorable outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3657/abstract/17,18\">",
"     17,18",
"    </a>",
"    ], the patient with heart disease may not have adequate cardiac reserve to withstand complications of childbirth [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3657/abstract/19\">",
"     19",
"    </a>",
"    ]. Thus, the anesthetic management should include contingency plans for complications such as peripartum arrhythmias, pulmonary edema, postpartum hemorrhage, or need for emergent cesarean delivery.",
"   </p>",
"   <p>",
"    In patients at high risk for cardiac morbidity or mortality, a direct conversation with the cardiologist to discuss pertinent concerns should occur. If maternal condition is tenuous or terminal, consideration should be given to discussing her resuscitative wishes in the event of cardiopulmonary arrest.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Labor analgesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excellent labor analgesia is of paramount importance in laboring women with cardiac lesions. Pain and anxiety during labor and delivery provoke catecholamine surges, resulting in tachycardia, hypertension, increased cardiac output, and increased systemic ventricular stress. This can be catastrophic for the patient with heart disease, who may develop arrhythmias, ischemia, or heart failure.",
"   </p>",
"   <p>",
"    Either an epidural or a combined spinal-epidural (CSE) anesthetic can be performed safely for most patients with cardiac disease. If a rapid decrease in preload and afterload are likely to compromise cardiac status, then we eliminate local anesthetics from the intrathecal portion of the CSE, and only administer intrathecal opioids. In such patients, the epidural should be dosed slowly with local anesthetics to maintain stable hemodynamics and adequate uteroplacental blood flow. This technique carries the risk of a potential delay in discovery of a poorly placed epidural catheter after a CSE; however, epidural catheters placed during a CSE are less likely to fail [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3657/abstract/20\">",
"     20",
"    </a>",
"    ]. An epidural-only technique is an alternative option. Either a CSE or an epidural is a reasonable approach since both provide excellent analgesia with local anesthetic dosing.",
"   </p>",
"   <p>",
"    We suggest using the loss of resistance technique with saline rather than air in order to avoid paradoxical air embolism if the epidural needle is inadvertently placed into an epidural vein. Women with intracardiac shunts are at risk for paradoxical air embolus.",
"   </p>",
"   <p>",
"    The risks and benefits of test dosing with an epinephrine solution need to be considered on a case-by-case basis, as even a small dose of epinephrine in these patients could result in tachyarrhythmias and increased systemic ventricular stress. Conversely,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    toxicity from intravascular injection or a total spinal from intrathecal injection could be catastrophic for any patient, especially those with heart disease.",
"   </p>",
"   <p>",
"    If neuraxial analgesia is not an option for a high-risk cardiac patient, then the advisability of vaginal delivery may need to be reconsidered. Although patient-controlled analgesia (PCA) via intravascular opioid infusion with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/50/5927?source=see_link\">",
"     remifentanil",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    is performed in many patients, this may not be a good alternative for the cardiac patient. Pain control is typically suboptimal, leading to increased catecholamine release. Furthermore, to achieve even moderately effective analgesia, the dose of opioid required could suppress ventilation. The resultant carbon dioxide retention can cause respiratory acidosis, further catecholamine release, and increased pulmonary hypertension leading to arrhythmias, ischemia, or heart failure in the high risk cardiac patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Monitoring during labor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard labor monitoring, including noninvasive blood pressure measurement, tocodynamometry, and fetal heart rate monitoring should be employed, with consideration of five-lead telemetry and continuous pulse oximetry. We suggest telemetry during labor for patients at increased risk of developing arrhythmias and pulse oximetry for patients with cyanotic CHD or right-to-left vascular shunting. The addition of more invasive monitors during labor, such as arterial blood pressure and central venous pressure monitoring, depends upon the stability of the patient. As an example, if the woman develops progressive dyspnea, arterial and perhaps central venous pressure monitoring may better characterize the effects of uterine contractions and maternal expulsive efforts on overall hemodynamics, and guide obstetric and anesthetic interventions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Surgical anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision regarding the type of anesthesia for cesarean delivery in a pregnant woman with a cardiac lesion is very important. The paramount decision is whether to perform general or neuraxial anesthesia. With CHD, maintenance of spontaneous respirations with a neuraxial approach may result in fewer cardiopulmonary complications because many congenital heart lesions affect lung mechanics and alveolar gas exchange. Alternatively, if there is a high probability of intraoperative complications requiring emergent induction and establishment of an airway, some anesthesiologists recommend planned general anesthesia.",
"   </p>",
"   <p>",
"    In some cases, the choice of regional versus general anesthesia is clearly dictated by obstetric or anesthetic indications. As an example, a history of a difficult airway or a family history of malignant hyperthermia favors a regional anesthetic, while an emergent obstetric situation or a significant coagulopathy necessitates general anesthesia as the safer choice. Specific cardiac indications for general versus regional are few; most anesthesiologists would agree with Dobb and Yentis, who state: \"the care with which each technique is used, rather than the technique itself, is most important\" [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3657/abstract/21\">",
"     21",
"    </a>",
"    ]. A summary of factors that should be taken into account when weighing the cardiac considerations of regional versus general techniques is shown in the table (",
"    <a class=\"graphic graphic_table graphicRef76327 \" href=\"UTD.htm?36/17/37148\">",
"     table 2",
"    </a>",
"    ). However, the anesthetic management of each patient needs to be considered individually.",
"   </p>",
"   <p>",
"    If regional anesthesia is chosen, then the anesthesiologist must decide between a single-shot spinal, an epidural, a combined spinal-epidural (CSE), or a continuous spinal technique. The rapid decrease in preload and afterload associated with a single shot spinal may be contraindicated in some cardiac lesions (eg, mitral stenosis, aortic stenosis, aortic coarctation, or right-to-left shunting). An epidural dosed slowly with appropriate monitoring and vigilance is likely to result in the least cardiovascular disruption. Some anesthesiologists argue that, in lesions that involve left ventricular outflow tract obstruction, an epidural for surgical anesthesia is contraindicated; however, epidural anesthesia for cesarean delivery has been reported to be well tolerated even in severe aortic stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3657/abstract/22\">",
"     22",
"    </a>",
"    ]. Addition of an opioid when dosing the neuraxial anesthetic will reduce the amount of local anesthetic required while improving both intraoperative and postoperative analgesia. The elimination of epinephrine from the epidural dose will eliminate the possible deleterious effects of systemic epinephrine.",
"   </p>",
"   <p>",
"    An alternative to a single-shot spinal or epidural technique is a low-dose CSE technique. In one report where this approach was used in four high-risk cardiac patients, CSE was performed with an intrathecal dose of 4 to 5 mg of heavy",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    along with 20 to 25 mcg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    , followed by slow loading of the epidural local anesthetic to achieve a T4 surgical level [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3657/abstract/23\">",
"     23",
"    </a>",
"    ]. The purported benefits of the low-dose CSE technique include a slower-onset of the neuraxial block, which may allow the anesthesiologist to maintain preload and afterload during the onset, while still achieving the greater block reliability of intrathecal local anesthetic administration. One study has found no difference in cardiac output or the incidence of hypotension regardless of whether 5 mg or 10 mg intrathecal bupivacaine was administered during a CSE [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3657/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The anesthesiologist must remain vigilant during the onset of neuraxial surgical anesthesia. Maintaining uterine blood flow is important for fetal well-being and, in patients with intravascular shunting, maintaining systemic vascular resistance is important for preventing worsening cyanosis. Cautious intravenous hydration",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    gentle titration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/36/39488?source=see_link\">",
"     phenylephrine",
"    </a>",
"    or ephedrine are options to counteract the hemodynamic effects of surgical neuraxial block. If symptomatic hypotension occurs, the choice of vasoactive drugs depends upon multiple factors. As an example, phenylephrine to treat hypotension in the presence of tachycardia would also be expected to reduce the heart rate, while ephedrine would increase the heart rate when used to treat hypotension in the presence of bradycardia. Phenylephrine in the presence of an intracardiac shunt would increase pulmonary blood flow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Intraoperative monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the American Society of Anesthesiology (ASA) recommendations for standard operating room monitors [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3657/abstract/25\">",
"     25",
"    </a>",
"    ], arterial blood pressure and central venous pressure monitoring may be helpful in fluid management, especially in the event of intraoperative hemorrhage or heart failure. As an example, in peripartum cardiomyopathy, if the patient has pulmonary edema and decreased ejection fraction, fluid management can be difficult. Central venous pressure monitoring can help with titration of fluids or vasopressor agents. If an arterial line",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    central venous catheter are planned, we recommend placement prior to administration of regional anesthesia. A unique aspect of placing invasive monitors for a cesarean delivery is that the patient is usually awake during the procedure. Should a general anesthetic be planned, placement of lines prior to induction will minimize fetal anesthetic exposure prior to delivery.",
"   </p>",
"   <p>",
"    The American Society of Anesthesiologists (ASA) practice advisory for perioperative management addresses use of automated implanted cardiac defibrillators (AICD) and pacemakers [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3657/abstract/26\">",
"     26",
"    </a>",
"    ]. They recommend that the anesthesiologist determine the type of pacemaker",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    AICD, the patient's dependency on it, and its current function through interrogation of the device. After consulting with the cardiology team in complex cases, it may be appropriate to reprogram the pacemaking device to an asynchronous mode",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    turn the AICD off for surgical cases that involve unipolar cautery. This prevents electromechanical interference. The placement of external defibrillation pads on the patient and the rapid availability of a cardiac defibrillator are recommended when an AICD is inactivated.",
"   </p>",
"   <p>",
"    Filters should be placed on all intravenous lines to prevent paradoxical air embolism in patients with intracardiac shunts. Echocardiography may be useful in the setting of cardiovascular compromise, and transesophageal imaging can be performed intraoperatively.",
"   </p>",
"   <p>",
"    Pulmonary arterial (PA) catheter monitoring is rarely indicated. The risk of complications from these catheters may be increased in this population because of conduction and anatomic abnormalities inherent to the patient's heart lesion. The merits of direct monitoring should be carefully weighed against the risks of arrhythmia and infections on an individual basis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27128?source=see_link\">",
"     \"Pulmonary artery catheterization: Indications and complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     ENDOCARDITIS PROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association Task Force on Practice Guidelines: endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons state vaginal or cesarean delivery is not an indication for routine antibiotic prophylaxis since the rate of bacteremia with these procedures is low [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3657/abstract/27\">",
"     27",
"    </a>",
"    ]. However, antibiotic prophylaxis may be considered in some particularly high risk circumstances. These patients and the guidelines are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=see_link&amp;anchor=H15#H15\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\", section on 'Vaginal or cesarean delivery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     MEDICAL MANAGEMENT OF POSTPARTUM HEMORRHAGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The medical management of postpartum hemorrhage in a woman with cardiac disease needs to consider the patient's cardiac status, medical history, and side effects of the various uterotonic drugs. The following medications are listed in the order we consider their use for treatment of uterine atony in women with heart disease and postpartum hemorrhage. A detailed discussion of treatment of postpartum hemorrhage in the general obstetrical population can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/38/42600?source=see_link\">",
"     \"Overview of postpartum hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     First-line therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    (Pitocin&reg;) for prevention and initial medical therapy of postpartum hemorrhage.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Generally administered as a continuous infusion of 10 to 40 units",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"       oxytocin",
"      </a>",
"      diluted in 500 to 1000 mL crystalloid. Side effects include decrease in mean arterial pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?3/36/3657/abstract/28\">",
"       28",
"      </a>",
"      ], decrease in total peripheral vascular resistance decreases [",
"      <a class=\"abstract\" href=\"UTD.htm?3/36/3657/abstract/28\">",
"       28",
"      </a>",
"      ], and possibly a slight increase in pulmonary artery pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?3/36/3657/abstract/29\">",
"       29",
"      </a>",
"      ]. Side effects occur more frequently with intravenous bolus administration.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"       Oxytocin",
"      </a>",
"      has a short half-life; cardiovascular changes typically last less than 10 minutes after the infusion is discontinued.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Second-line therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     Misoprostol",
"    </a>",
"    (Cytotec&reg;) is a prostaglandin E1 analogue.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Administered as a rectal suppository (600 to 1000 mcg) or placed in the patient's cheek for transbuccal absorption. The patient should be instructed not to swallow these pills because gastrointestinal upset and diarrhea can occur.",
"     </li>",
"     <li>",
"      Maternal cardiac function remains unchanged even with high doses [",
"      <a class=\"abstract\" href=\"UTD.htm?3/36/3657/abstract/30\">",
"       30",
"      </a>",
"      ]. Cardiovascular adverse drug reactions have been noted in fewer than 2 percent of patients, but causality has not been established.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Third-line therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/29/20948?source=see_link\">",
"     Carboprost tromethamine",
"    </a>",
"    (Hemabate&reg;) is 15-methyl prostaglandin F2 alpha.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Administered as an intramuscular injection of 250 mcg.",
"     </li>",
"     <li>",
"      Contraindicated in patients with reactive airway disease. Side effects include bronchospasm [",
"      <a class=\"abstract\" href=\"UTD.htm?3/36/3657/abstract/31\">",
"       31",
"      </a>",
"      ] and altered",
"      <span class=\"nowrap\">",
"       ventilation/perfusion",
"      </span>",
"      ratio resulting in increased intrapulmonary shunt fraction and possibly hypoxemia [",
"      <a class=\"abstract\" href=\"UTD.htm?3/36/3657/abstract/32\">",
"       32",
"      </a>",
"      ]. These side effects can lead to worsening cyanosis in patients with an intracardiac shunt.",
"     </li>",
"     <li>",
"      May induce hypertension at high doses, possibly because of vascular smooth muscle contraction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Fourth-line therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methergonivine (Methergine&reg;), which most likely exerts its uterotonic effect via alpha-1 receptor stimulation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Administered as a 0.2 mg intramuscular injection (intravascular injection should be avoided)",
"     </li>",
"     <li>",
"      Relatively contraindicated in patients with heart disease, especially those with hypertension or preeclampsia. Side effects, which are more significant with bolus intravenous injection, include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Vasoconstriction leading to sudden, systemic hypertension. This could cause stroke or seizure [",
"      <a class=\"abstract\" href=\"UTD.htm?3/36/3657/abstract/33\">",
"       33",
"      </a>",
"      ], especially in patients with baseline hypertension.",
"     </li>",
"     <li>",
"      Coronary vasospasm (causing myocardial infarction)",
"     </li>",
"     <li>",
"      Increased pulmonary artery pressure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     POSTPARTUM CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intensity of postpartum monitoring is determined by the status of the patient's heart disease and any obstetric or cardiac events that occurred during labor and delivery. In general, hemodynamics do not return to prepregnancy values until 6 to 12 weeks following delivery. Cardiac death during this period has been reported, especially in women with pulmonary hypertension, so careful monitoring for cardiac symptoms is important [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3657/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Major hemodynamic changes occur during pregnancy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Hemodynamic changes during pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cardiac lesions can be stratified according to their risk of death or severe morbidity during pregnancy (",
"      <a class=\"graphic graphic_table graphicRef74878 \" href=\"UTD.htm?32/48/33548\">",
"       table 1",
"      </a>",
"      ). However, patient-specific factors&nbsp;must be taken into account. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Risk stratification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cesarean delivery is rarely performed solely for a maternal cardiac indication. Exceptions include some types of aortic disease and fetal anticoagulation. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Cesarean delivery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A \"cardiac\" vaginal delivery refers to modifications of the usual management of labor and delivery to accommodate the hemodynamic limitations of the patient with heart disease. It involves early, deep regional anesthesia and avoidance of maternal Valsalva efforts. In most parturients with congenital heart disease, however, it is reasonable to attempt a trial of Valsalva maneuver in the second stage of labor. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Vaginal delivery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Paradoxical air embolism should be prevented in patients with intracardiac right-to-left shunting by avoiding air entrapment in intravenous lines and by performing loss of resistance to saline instead of air during epidural catheter placement. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Anesthetic management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Epidural or a combined spinal-epidural (CSE) are preferred for most patients with cardiac disease. For women undergoing cesarean delivery, factors that should be taken into account when weighing the cardiac considerations of regional versus general techniques are shown in the table (",
"      <a class=\"graphic graphic_table graphicRef76327 \" href=\"UTD.htm?36/17/37148\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Labor analgesia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Surgical anesthesia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest telemetry during labor for patients at increased risk of developing arrhythmias, and pulse oximetry for patients with cyanotic heart disease or those with right-to-left vascular shunting. The addition of more invasive monitors for labor, such as arterial blood pressure and central venous pressure monitoring, depends upon the stability of the patient. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Monitoring during labor'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For treatment of postpartum hemorrhage, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"       oxytocin",
"      </a>",
"      (Pitocin&reg;) as a first-line agent and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      (Cytotec&reg;) as a second-line agent, given they are associated with fewer cardiorespiratory effects than 15-Methyl prostaglandin F2 alpha (Hemabate&reg;) and Methergonivine (Methergine&reg;) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Medical management of postpartum hemorrhage'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3657/abstract/1\">",
"      European Society of Gynecology (ESG), Association for European Paediatric Cardiology (AEPC), German Society for Gender Medicine (DGesGM), et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J 2011; 32:3147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3657/abstract/2\">",
"      Ueland K, Hansen JM. Maternal cardiovascular dynamics. II. Posture and uterine contractions. Am J Obstet Gynecol 1969; 103:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3657/abstract/3\">",
"      Kjeldsen J. Hemodynamic investigations during labour and delivery. Acta Obstet Gynecol Scand Suppl 1979; 89:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3657/abstract/4\">",
"      Robson SC, Dunlop W, Moore M, Hunter S. Combined Doppler and echocardiographic measurement of cardiac output: theory and application in pregnancy. Br J Obstet Gynaecol 1987; 94:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3657/abstract/5\">",
"      Tihtonen K, K&ouml;&ouml;bi T, Yli-Hankala A, Uotila J. Maternal hemodynamics during cesarean delivery assessed by whole-body impedance cardiography. Acta Obstet Gynecol Scand 2005; 84:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3657/abstract/6\">",
"      Doyle P. The outcome of multiple pregnancy. Hum Reprod 1996; 11 Suppl 4:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3657/abstract/7\">",
"      Siu SC, Sermer M, Colman JM, et al. Prospective multicenter study of pregnancy outcomes in women with heart disease. Circulation 2001; 104:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3657/abstract/8\">",
"      Khairy P, Ouyang DW, Fernandes SM, et al. Pregnancy outcomes in women with congenital heart disease. Circulation 2006; 113:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3657/abstract/9\">",
"      van Mook WN, Peeters L. Severe cardiac disease in pregnancy, part I: hemodynamic changes and complaints during pregnancy, and general management of cardiac disease in pregnancy. Curr Opin Crit Care 2005; 11:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3657/abstract/10\">",
"      Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:e523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3657/abstract/11\">",
"      Vahanian A, Baumgartner H, Bax J, et al. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 2007; 28:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3657/abstract/12\">",
"      Jastrow N, Meyer P, Khairy P, et al. Prediction of complications in pregnant women with cardiac diseases referred to a tertiary center. Int J Cardiol 2011; 151:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3657/abstract/13\">",
"      Drenthen W, Boersma E, Balci A, et al. Predictors of pregnancy complications in women with congenital heart disease. Eur Heart J 2010; 31:2124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3657/abstract/14\">",
"      Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008 Guidelines for the Management of Adults with Congenital Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to develop guidelines on the management of adults with congenital heart disease). Circulation 2008; 118:e714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3657/abstract/15\">",
"      Arendt KW, Fernandes SM, Khairy P, et al. A case series of the anesthetic management of parturients with surgically repaired tetralogy of Fallot. Anesth Analg 2011; 113:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3657/abstract/16\">",
"      Ouyang DW, Khairy P, Fernandes SM, et al. Obstetric outcomes in pregnant women with congenital heart disease. Int J Cardiol 2010; 144:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3657/abstract/17\">",
"      Ford AA, Wylie BJ, Waksmonski CA, Simpson LL. Maternal congenital cardiac disease: outcomes of pregnancy in a single tertiary care center. Obstet Gynecol 2008; 112:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3657/abstract/18\">",
"      Maxwell BG, El-Sayed YY, Riley ET, Carvalho B. Peripartum outcomes and anaesthetic management of parturients with moderate to complex congenital heart disease or pulmonary hypertension*. Anaesthesia 2013; 68:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3657/abstract/19\">",
"      Goldszmidt E, Macarthur A, Silversides C, et al. Anesthetic management of a consecutive cohort of women with heart disease for labor and delivery. Int J Obstet Anesth 2010; 19:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3657/abstract/20\">",
"      Pan PH, Bogard TD, Owen MD. Incidence and characteristics of failures in obstetric neuraxial analgesia and anesthesia: a retrospective analysis of 19,259 deliveries. Int J Obstet Anesth 2004; 13:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3657/abstract/21\">",
"      Dob DP, Yentis SM. Practical management of the parturient with congenital heart disease. Int J Obstet Anesth 2006; 15:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3657/abstract/22\">",
"      Ioscovich AM, Goldszmidt E, Fadeev AV, et al. Peripartum anesthetic management of patients with aortic valve stenosis: a retrospective study and literature review. Int J Obstet Anesth 2009; 18:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3657/abstract/23\">",
"      Hamlyn EL, Douglass CA, Plaat F, et al. Low-dose sequential combined spinal-epidural: an anaesthetic technique for caesarean section in patients with significant cardiac disease. Int J Obstet Anesth 2005; 14:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3657/abstract/24\">",
"      Bray JK, Fernando R, Patel NP, Columb MO. Suprasternal Doppler estimation of cardiac output: standard versus sequential combined spinal epidural anesthesia for cesarean delivery. Anesth Analg 2006; 103:959.",
"     </a>",
"    </li>",
"    <li>",
"     American Society of Anesthesiology House of Delegates. Standards for Basic Anesthetic Monitoring. In: ASA Standards Guidelines and Statements, 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3657/abstract/26\">",
"      American Society of Anesthesiologists Task Force on Perioperative Management of Patients with Cardiac Rhythm Management Devices. Practice advisory for the perioperative management of patients with cardiac rhythm management devices: pacemakers and implantable cardioverter-defibrillators: a report by the American Society of Anesthesiologists Task Force on Perioperative Management of Patients with Cardiac Rhythm Management Devices. Anesthesiology 2005; 103:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3657/abstract/27\">",
"      Nishimura RA, Carabello BA, Faxon DP, et al. ACC/AHA 2008 guideline update on valvular heart disease: focused update on infective endocarditis: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3657/abstract/28\">",
"      Weis FR Jr, Markello R, Mo B, Bochiechio P. Cardiovascular effects of oxytocin. Obstet Gynecol 1975; 46:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3657/abstract/29\">",
"      Secher NJ, Arnsbo P, Wallin L. Haemodynamic effects of oxytocin (syntocinon) and methyl ergometrine (methergin) on the systemic and pulmonary circulations of pregnant anaesthetized women. Acta Obstet Gynecol Scand 1978; 57:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3657/abstract/30\">",
"      Ramsey PS, Hogg BB, Savage KG, et al. Cardiovascular effects of intravaginal misoprostol in the mid trimester of pregnancy. Am J Obstet Gynecol 2000; 183:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3657/abstract/31\">",
"      O'Leary AM. Severe bronchospasm and hypotension after 15-methyl prostaglandin F(2alpha) in atonic post partum haemorrhage. Int J Obstet Anesth 1994; 3:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3657/abstract/32\">",
"      Andersen LH, Secher NJ. Pattern of total and regional lung function in subjects with bronchoconstriction induced by 15-me PGF2 alpha. Thorax 1976; 31:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3657/abstract/33\">",
"      Abouleish E. Postpartum hypertension and convulsion after oxytocic drugs. Anesth Analg 1976; 55:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3657/abstract/34\">",
"      Dob DP, Yentis SM. UK registry of high-risk obstetric anaesthesia: report on cardiorespiratory disease. Int J Obstet Anesth 2001; 10:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3657/abstract/35\">",
"      Bonnin M, Mercier FJ, Sitbon O, et al. Severe pulmonary hypertension during pregnancy: mode of delivery and anesthetic management of 15 consecutive cases. Anesthesiology 2005; 102:1133.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4446 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-40244E071D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_36_3657=[""].join("\n");
var outline_f3_36_3657=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HEMODYNAMIC CHANGES DURING PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Antepartum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Intrapartum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Cesarean delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Multiple gestation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      RISK STRATIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      OBSTETRICAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Indications for cesarean delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Vaginal delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ANESTHETIC MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Preoperative evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Labor analgesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Monitoring during labor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Surgical anesthesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Intraoperative monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      ENDOCARDITIS PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      MEDICAL MANAGEMENT OF POSTPARTUM HEMORRHAGE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      First-line therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Second-line therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Third-line therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Fourth-line therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      POSTPARTUM CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/4446\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4446|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/59/37821\" title=\"figure 1A\">",
"      Hemodynamic changes in normal pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/32/9742\" title=\"figure 1B\">",
"      Blood volume in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/50/38703\" title=\"figure 1C\">",
"      Cardiac output in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/37/4702\" title=\"figure 2A\">",
"      Cardiac output during labor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/1/40982\" title=\"figure 2B\">",
"      Hemodynamics with contractions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4446|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/48/33548\" title=\"table 1\">",
"      Risk stratification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/17/37148\" title=\"table 2\">",
"      Anesthesia choice in pregnant women with cardiac disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/26/17832?source=related_link\">",
"      Abnormalities of coagulation and platelet function in preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29097?source=related_link\">",
"      Acquired heart disease and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/2/39977?source=related_link\">",
"      Anesthesia for cesarean delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/2/32808?source=related_link\">",
"      Expectant management of severe preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/34/1577?source=related_link\">",
"      Management of heart failure in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20105?source=related_link\">",
"      Maternal cardiovascular and hemodynamic adaptations to pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/39/15994?source=related_link\">",
"      Operative vaginal delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/38/42600?source=related_link\">",
"      Overview of postpartum hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=related_link\">",
"      Preeclampsia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21882?source=related_link\">",
"      Preeclampsia: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29818?source=related_link\">",
"      Pregnancy in women with congenital heart disease: General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/21/35159?source=related_link\">",
"      Pregnancy in women with congenital heart disease: Specific lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27128?source=related_link\">",
"      Pulmonary artery catheterization: Indications and complications",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_36_3658="Peptic ulcer disease: Genetic, environmental, and psychological risk factors and pathogenesis";
var content_f3_36_3658=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Peptic ulcer disease: Genetic, environmental, and psychological risk factors and pathogenesis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/36/3658/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/36/3658/contributors\">",
"     Andrew H Soll, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/36/3658/contributors\">",
"     Nimish B Vakil, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/36/3658/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/36/3658/contributors\">",
"     Mark Feldman, MD, MACP, AGAF, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/36/3658/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/36/3658/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/36/3658/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peptic ulcers are defects in the gastrointestinal mucosa that extend through the muscularis mucosae. They persist as a function of the acid or peptic activity in gastric juice. Peptic ulcer disease (PUD) is an important cause of morbidity and health care costs. The natural history of peptic ulcer ranges from resolution without intervention to the development of complications with the potential for significant morbidity and mortality, such as bleeding and perforation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42281?source=see_link\">",
"     \"Overview of the natural history and treatment of peptic ulcer disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/21/40282?source=see_link\">",
"     \"Overview of the complications of peptic ulcer disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will summarize the pathogenesis and risk factors of PUD. A review of its epidemiology and major causes is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/42/19113?source=see_link\">",
"     \"Epidemiology and etiology of peptic ulcer disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Considering the acid-peptic environment of the stomach and the noxious agents that are ingested, ulcers are surprisingly uncommon, illustrating the importance of protective mechanisms that govern gastric mucosal function and repair. Primary malfunction of these secretory, defense, or repair mechanisms is a very uncommon cause of ulcer, if it occurs at all. Most ulcers occur when the normal mechanisms are disrupted by superimposed processes such as Helicobacter pylori infection and the ingestion of nonsteroidal antiinflammatory drugs (NSAIDs).",
"   </p>",
"   <p>",
"    The decreasing prevalence of H. pylori infection has had a significant impact on the burden of ulcer disease in both developed and developing countries. In developed countries such as the United States, the prevalence of ulcer disease in young people has declined, while NSAID-related ulcers in older adults have increased due both to the increasing in life expectancy and the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and NSAIDs [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Helicobacter pylori",
"    </span>",
"    &nbsp;&mdash;&nbsp;Helicobacter pylori affects a number of aspects of intestinal and mucosal physiology including gastric acid secretion, gastric metaplasia, immune responses, and mucosal defense mechanisms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44679?source=see_link\">",
"     \"Association between Helicobacter pylori infection and duodenal ulcer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Nonsteroidal antiinflammatory drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;NSAIDs, via inhibition of prostaglandin synthesis, affect the amount of gastric acid generated, the integrity of the mucosal barrier, the amount of bicarbonate and glutathione generated, and the rate of mucosal blood flow. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6745?source=see_link\">",
"     \"NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the understanding that the majority of peptic ulcer disease (PUD) is related to H. pylori or NSAIDs, gastroduodenal ulcers are still \"peptic\". With very few exceptions, complete pharmacologic inhibition of acid secretion induces ulcer healing and prevents recurrence. As a result, multiple factors are involved in the pathophysiology of most peptic ulcers.",
"   </p>",
"   <p>",
"    Thus, the presence of H. pylori or use of NSAIDs alone is not likely to be sufficient for ulcer formation. Although gastritis is consistently observed with H. pylori infection and NSAIDs consistently inhibit mucosal prostaglandin production, the yearly incidence of clinical ulcer disease among subjects at risk is only about 1 percent for both categories of ulcer [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/5-7\">",
"     5-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are a number of risk factors for ulcer disease, described below, such as smoking and increased acid and decreased duodenal bicarbonate secretion. Although these factors are almost certainly of pathogenic relevance, the extent to which these three mechanisms distinguish the small subset with H. pylori exposure that develop ulcers from the similarly-exposed majority who remain ulcer-free has not been established.",
"   </p>",
"   <p>",
"    Mucosal damage from trauma, acid-peptic activity, and exposure to environmental toxins occurs in everyone on a daily basis, and the gastrointestinal mucosa has a remarkable ability to repair itself. Chronic peptic ulcers, which are focal mucosal lesions that persist or recur over time, usually in the same location, are the exception.",
"   </p>",
"   <p>",
"    The following section reviews the mechanisms that contribute to peptic ulcer formation. Unfortunately, there are limited data comparing H. pylori-positive ulcer subjects to H. pylori-positive controls, and non-infected controls. There are virtually no data comparing pathogenic mechanisms in subjects who develop NSAID ulcers with subjects exposed to NSAIDs who remain ulcer free. Similarly, there are very limited studies of pathogenic mechanisms in patients with non-HP, non-NSAID ulcers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Gastric acid hypersecretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although only a small proportion of duodenal ulcer (DU) subjects have true acid hypersecretion, high normal or modestly elevated values appear to be a defining characteristic of patients with DU, whether or not they are infected with H. pylori.",
"   </p>",
"   <p>",
"    Among H. pylori-positive subjects with DU, three factors appear to contribute to the high-normal or high levels of acid secretion:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A subset has hypergastrinemia that is H. pylori-dependent, since cure of the infection leads to a decrease in acid secretion [",
"      <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A subset has an H. pylori-independent drive to acid secretion, possibly related to vagal hyperactivity [",
"      <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/9,10\">",
"       9,10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      DU patients generally have sparing of their acid-secreting gastric body from gastritis and atrophy, leaving the parietal cell mass intact and capable of producing robust levels of acid secretion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Relative hypergastrinemia is seen in H. pylori-infected subjects with or without DU; the causal elements appear to be suppression of somatostatin, rather than an increase in gastrin-secreting cells [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/11\">",
"     11",
"    </a>",
"    ]. The abnormality in acid secretion seen in DU subjects is linked to the predisposition in the host, rather than directly to H. pylori infection. The defective regulation of acid secretion in DU appears to be related to impaired control of inhibitory mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/12\">",
"     12",
"    </a>",
"    ], although defective inhibitory regulation is also seen in people without DU. The abnormalities in gastrin and somatostatin secretion and most abnormalities of acid secretion normalize within one year of H. pylori eradication [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/8,12\">",
"     8,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ulcer recurrence following successful H. pylori eradication may be more common than previously expected [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/13\">",
"     13",
"    </a>",
"    ]. A small study found higher basal and pentagastrin-stimulated acid secretion in patients with recurrent ulcers following successful H. pylori eradication, compared to patients without recurrent ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among H. pylori-negative subjects, a subset has acid hypersecretion without hypergastrinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/10,15\">",
"     10,15",
"    </a>",
"    ]. The mechanisms of acid hypersecretion in these patients have not been defined. One study of six patients with non-HP, non-NSAID DU found increased gastrin response to a meal (but not fasting hypergastrinemia) and increased peak gastric acid secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/16\">",
"     16",
"    </a>",
"    ]. Some subjects with non-HP, non-NSAID hypersecretion may have a component of muscarinic-dependent, vagal hyperactivity, although this element is difficult to quantify. In the absence of H. pylori or gastrinoma, fasting hypergastrinemia is only rarely found in hypersecretory DU patients, sometimes linked to antral G cell hyperfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19466?source=see_link\">",
"     \"Unusual causes of peptic ulcer disease\"",
"    </a>",
"    .) Taken together, these data indicate that increased acid secretion is an important factor in some patients with ulcer recurrences following successful H. pylori eradication and in some patients with non-HP, non-NSAID DU.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Duodenal abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of DU patients have impaired duodenal bicarbonate secretion, which has also proven to be H. pylori-dependent, since cure of the infection reverses the defect [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44679?source=see_link\">",
"     \"Association between Helicobacter pylori infection and duodenal ulcer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The combination of increased gastric acid secretion and reduced duodenal bicarbonate secretion lowers the pH in the duodenum, which promotes the development of gastric metaplasia (ie, the presence of gastric epithelium in the first portion of the duodenum) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    H. pylori infection in areas of gastric metaplasia induces duodenitis and enhances the susceptibility to acid injury, thereby possibly predisposing to DU [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/19\">",
"     19",
"    </a>",
"    ]. A study that followed 181 pts with endoscopy-negative, non-ulcer dyspepsia and found that duodenal colonization by H. pylori was a highly significant predictor of the subsequent development of DU [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Excess acid secretion in gastrinoma patients is also associated with marked gastric metaplasia in the duodenum. Thus, metaplasia can be related to chronic injury can occur independently of H. pylori infection. Although it is possible that duodenal gastric metaplasia is simply a consequence of duodenal injury from acid or H. pylori, it is an attractive hypothesis that chronic, local duodenal mucosal injury ulcer actually predisposes to focal development of DU. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44679?source=see_link\">",
"     \"Association between Helicobacter pylori infection and duodenal ulcer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Gastric ulcer",
"    </span>",
"    &nbsp;&mdash;&nbsp;A gastric ulcer (GU) occurring in the stomach proximal to the distal antrum and prepyloric region is usually associated with low-normal or low acid secretion, reflecting a low normal parietal cell mass [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/7\">",
"     7",
"    </a>",
"    ]. These findings correspond to the encroachment of oxyntic mucosa by advancing antritis and oxyntic gland atrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/21\">",
"     21",
"    </a>",
"    ]. In contrast to GU involving the gastric body, patients with ulcers in the distal antrum or GU associated with concurrent DU have normal or even increased levels of acid secretion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     GENETIC, ENVIRONMENTAL, AND PSYCHOLOGICAL RISK FACTORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Familial aggregation and genetic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies from the pre-H. pylori era recognized familial aggregation of peptic ulcer disease (PUD) in a pattern suggesting polygenic inheritance. The familial aggregation of both DU and GU appeared distinct: first-degree relatives of patients with DU have a threefold increase in the prevalence of DU but not GU; in contrast, relatives of patients with GU have a threefold increase in the prevalence of GU but not DU [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/22\">",
"     22",
"    </a>",
"    ]. Hyperpepsinogenemia was proposed as a marker of autosomal dominant inheritance of predisposition to peptic ulcer. Subsequent follow-up of these same subjects revealed that this pattern of hyperpepsinogenemia was in fact due to familial clustering of H. pylori infection [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Questions have to be reframed for the H. pylori era: First, are genetic factors involved in predisposing to H. pylori infection or in predisposing to certain disease outcomes in infected individuals? Second, are there genetic factors that operate independently of H. pylori?",
"   </p>",
"   <p>",
"    Host factors appear to be important in predisposing to H. pylori infection and to disease outcomes, such as DU and gastric cancer. However, the number of emerging candidates is daunting and no studies have yet determined the universality of any single finding. Some of the variability may be due to different genetic makeup of the study populations and the relatively small size of the studies. However, it is likely that multiple host factors interact with multiple bacterial factors, making this area challenging to investigate and to integrate. Genetic polymorphism related to synergy between host (TNF alpha promoter) and bacterial (induced by contact with epithelium, or the iceA1 gene) factors have been related to DU in children [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the setting of H. pylori infection host polymorphisms involving the cytokine IL-1- beta [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/25,26\">",
"     25,26",
"    </a>",
"    ], but not IL-6 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/27\">",
"     27",
"    </a>",
"    ], are linked to DU, probably related to effects of H. pylori-associated inflammation and acid secretion. In a Japanese study, host polymorphisms in TNF-alpha rather than IL-1-beta were associated with increased risk for GU and gastric cancer, but not DU [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/28\">",
"     28",
"    </a>",
"    ]. The study included 110 GU, 94 DU, 105 gastric cancer patients, and HP-negative 172 controls. Other studies have been negative for both factors in DU [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although IL-1- beta has been reported to have cytoprotective effects [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/30\">",
"     30",
"    </a>",
"    ], it remains to be determined whether cytokine polymorphisms influence PUD in patients with other forms of PUD. One study involving samples from 200 patients with DU and GU and 342 healthy controls found that the",
"    <span class=\"nowrap\">",
"     TGFB1+869(*)C/C",
"    </span>",
"    genotype was associated with reduced risk of developing DU [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genetic polymorphism relating to cyclooxygenase-1 and PG production is another factor to consider. In an investigation of stocked DNA from 480 Japanese patients with a total of 93 GUs and 44 DUs, the T1676C COX-1 polymorphism was associated with GUs in non-NSAID users and with both GUs and DUs in NSAID users [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Twin studies provide evidence for a clear genetic predisposition to PUD that is independent of any predisposition to H pylori infection. An illustrative report found high concordance of a self-reported ulcer history in monozygotic, compared to dizygotic twins, regardless of whether they were reared apart or together [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/21\">",
"     21",
"    </a>",
"    ]. Cross-twin, cross-trait correlations for monozygotic and dizygotic twins indicated that genetic effects for peptic ulcer were independent of genetic influences for H. pylori. Another twin study also concluded that genetic factors were linked to DU, independent of environmental variables [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although hyperpepsinogenemia may be related to H. pylori infection, Italian investigators identified a family in which peptic ulcer was linked to elevated serum pepsinogen group A in the absence of H. pylori infection [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An association has been reported between peptic ulcer and several indirect \"genetic\" markers. Blood groups O and A, the Lewis phenotype Le(a + b-), and non-secretors of ABH in particular, have been associated for increased risk of peptic ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. However, other studies have failed to find any association of blood group O with H. pylori infection or with peptic ulcer [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. Thus, the relation between Lewis antigen expression, H. pylori attachment, and peptic ulcer disease is unclear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/44/4809?source=see_link\">",
"     \"Pathophysiology of and immune response to Helicobacter pylori infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Factors that influence the course of peptic ulcer",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of risk factors potentially impact the rate of ulcer healing, complications, and the tendency for recurrence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies primarily performed in the pre-H. pylori era found that smoking had an important facilitative role for peptic ulcer disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/40-43\">",
"     40-43",
"    </a>",
"    ]. Smokers were more likely to develop ulcers, and the ulcers were more difficult to treat and were associated with a higher rate of recurrence.",
"   </p>",
"   <p>",
"    In a prospective study of 7624 American men of Japanese ancestry in Hawaii, for example, the ulcer risk progressively increased with increasing pack-years of cigarette smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/44\">",
"     44",
"    </a>",
"    ]. A meta-analysis of English-language studies found that the general population risk attributable to cigarette smoking was 23 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/45\">",
"     45",
"    </a>",
"    ]. Although negative studies have been published [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/46\">",
"     46",
"    </a>",
"    ], the weight of evidence supports an association between smoking and PUD in H. pylori-infected subject [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/16,45,47\">",
"     16,45,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, smoking does",
"    <strong>",
"     not",
"    </strong>",
"    appear to be a risk factor for ulcer relapse once H. pylori has been eradicated [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. In one report, 256 patients with DU and 31 patients with GU were followed for up to 18 months after ulcer healing and successful eradication of H. pylori [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/48\">",
"     48",
"    </a>",
"    ]. Ulcer relapse occurred in 3 of 83 smokers (3.6 percent) versus 4 of 204 nonsmokers (2 percent), a difference which was not clinically significant. Smoking also did not influence recurrence of the H. pylori infection, which was observed in 4.8 and 4.4 percent of smokers and nonsmokers, respectively.",
"   </p>",
"   <p>",
"    There are conflicting data regarding whether smoking impairs the responsiveness of H. pylori to successful antibiotic cure [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. Thus, the general wisdom is that smoking is a risk factor for PUD before, but not after H. pylori eradication.",
"   </p>",
"   <p>",
"    Many mechanisms have been proposed to underlie the deleterious effects of smoking on mucosal aggressive and protective factors [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/50\">",
"     50",
"    </a>",
"    ]. As an example, smoking and chronic nicotine treatment stimulated basal acid output to a greater extent in smokers with DU history, compared to smokers without a DU history [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Nonsteroidal antiinflammatory drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonsteroidal antiinflammatory drugs (NSAIDs) are responsible for the majority of peptic ulcers not caused by H. pylori, and are associated with an increased risk of complications from peptic ulcer. NSAIDs cause de novo peptic ulcers and exacerbate underlying PUD disease due to H. pylori. In an illustrative study, medication histories of 494 patients with PUD were compared with 972 matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/51\">",
"     51",
"    </a>",
"    ]. The odds ratio for the development of GU and DU was 5.9 and 4.9, respectively, for NSAID users compared to controls. The odds ratio for the development of hemorrhage complicating a peptic ulcer was 5.2, as was the risk of perforation.",
"   </p>",
"   <p>",
"    NSAIDs are also responsible for a significant number of peptic ulcers that are refractory to conventional therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/52\">",
"     52",
"    </a>",
"    ]. Furthermore, up to 40 percent of patients may not report using NSAIDs suggesting that a high index of suspicion is required [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Characteristics of the patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several characteristics of the patient that may influence ulcer healing.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ulcers in older patients may heal more slowly than in younger individuals [",
"      <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/35,54-56\">",
"       35,54-56",
"      </a>",
"      ]. Older patients are also more likely to bleed, rebleed, require more transfusions, and have a prolonged hospital stay, probably due to the presence of comorbid illness [",
"      <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with simultaneous DU and GU may have delayed healing and a more complicated course.",
"     </li>",
"     <li>",
"      Patients who first develop ulcer complications in the hospital (stress ulcer) respond poorly to medical and surgical therapy. Stress ulcers are clearly related to pathophysiologic disturbances provoked by the underlying medical or surgical illness; they do poorly unless the underlying disease remits or responds to therapy. Despite a report that H. pylori-positive patients have an increased change of demonstrating marked mucosal injury [",
"      <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/58\">",
"       58",
"      </a>",
"      ], there is no evidence that stress ulcers are related to H. pylori infection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18776?source=see_link\">",
"       \"Stress ulcer prophylaxis in the intensive care unit\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Characteristics of the ulcer",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other factors may influence the natural history of peptic ulcer:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ulcer size is clearly an important factor that predicts healing rates. Giant ulcers are very slow to heal and require sustained treatment; surgery may occasionally be necessary for giant ulcers that cause complications before medical therapy has had a chance to work (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/18/13609?source=see_link\">",
"       \"Clinical manifestations of peptic ulcer disease\"",
"      </a>",
"      ). Large and small GUs heal at the same rate on antacids, about 3 mm per week [",
"      <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/59\">",
"       59",
"      </a>",
"      ]. Thus, larger ulcers will require more time to heal. Ulcer size also impacts healing rates for DU. In one study, for example, three risk factors were identified that were related to nonhealing of DU at four weeks: prior ulcer history, ulcer size, and smoking [",
"      <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/60\">",
"       60",
"      </a>",
"      ]. Ulcer healing was less likely in ulcers &ge;10 mm in diameter (62 percent), compared to smaller ulcers (76 percent).",
"     </li>",
"     <li>",
"      Dense scarring evident by deformity of the ulcer bed and surrounding mucosa leads to impaired healing and increased relapse rates. Stenosis or deformity of the duodenal bulb, detected radiographically or at endoscopy, predicts impaired healing and enhanced relapse rates [",
"      <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/61-64\">",
"       61-64",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Alcohol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alcohol in high concentrations damages the gastric mucosal barrier to hydrogen ions and is associated with acute gastric mucosal lesions characterized by mucosal hemorrhages. Alcohol also stimulates acid secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/65\">",
"     65",
"    </a>",
"    ]. In addition, contents of alcoholic beverages other than alcohol are also strong stimulants of acid secretion.",
"   </p>",
"   <p>",
"    Despite these acute effects, there is no evidence that alcohol intake causes or exacerbates chronic peptic ulcer disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/46,66\">",
"     46,66",
"    </a>",
"    ]. Modest alcohol consumption may even promote ulcer healing [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/54,67\">",
"     54,67",
"    </a>",
"    ]. In contrast, alcohol abuse interferes with patient compliance and ulcer healing [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;Folklore has incriminated dietary indiscretion as a cause of ulcers. Although certain foods, beverages, and spices cause dyspepsia, there are no convincing data that such specific foods cause, perpetuate, or reactivate peptic ulcers. There are, however, some data that implicate dietary factors may influence peptic ulcer pathogenesis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dietary factors have been hypothesized to account for some of the regional variation of ulcer disease, possibly related to toxins generated with storage of certain foods or from protective effects of certain foods. DU has been reported to be much more common in the rice-eating southern regions of India, compared to the wheat-eating Northern regions [",
"      <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/69\">",
"       69",
"      </a>",
"      ]. Animal studies indicated that whereas freshly milled rice and unmilled rice were protective against damaging agents such as alcohol, stored rice bran and its oil exacerbated mucosal damage [",
"      <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/70\">",
"       70",
"      </a>",
"      ]. Similarly, unrefined wheat or wheat bran were protective against damage, whereas refined wheat and wheat germ were not. In South Africa, DU has been reported to be very uncommon in rural areas, where home-pounded maize is a staple of the diet, compared to urban areas. Animal studies indicate that home-pounded maize gives protection against DU, whereas commercially-manufactured maize does not [",
"      <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/71\">",
"       71",
"      </a>",
"      ]. One can only speculate whether these animal models are relevant to human disease; these theories have not been directly tested in human studies.",
"      <br/>",
"      <br/>",
"      Other dietary factors also may be protective. One study found a much lower consumption of chili peppers by DU patients, compared to controls, prompting the hypothesis chili peppers protected against damage, possibly by activating mucosal adaptation [",
"      <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Dietary insufficiency of essential fatty acids has been proposed as a pathogenic factor in DU, possibly resulting in depletion of mucosal prostanoids [",
"      <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/73\">",
"       73",
"      </a>",
"      ]. It has also been suggested that an increase in dietary polyunsaturated fatty acids was protective against H. pylori. Supporting evidence for these hypotheses remains weak. One study compared the effects of a diet containing polyunsaturated fatty acids versus placebo in patients with peptic ulcer and H. pylori infection [",
"      <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/74\">",
"       74",
"      </a>",
"      ]. Fatty acids had no effect on either colonization of the stomach by H. pylori or antral prostaglandin levels. Similarly, a prospective study of a cohort of 47,806 men found no association between the type or amount of fat intake and the risk of DU [",
"      <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/75\">",
"       75",
"      </a>",
"      ]. However, high consumption of fruits and vegetables, dietary fiber, and vitamin A were associated with a reduced risk of ulcer disease.",
"     </li>",
"     <li>",
"      Coffee is a strong stimulant of acid secretion and produces dyspepsia in many individuals, which often results from enhanced esophageal reflux [",
"      <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/76\">",
"       76",
"      </a>",
"      ]. Caffeine is not the only variable, because decaffeination does not reduce these effects of coffee [",
"      <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/76\">",
"       76",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Despite these observations, there is no evidence that coffee consumption is a risk factor for ulcer disease, although increased consumption may be associated with a higher rate of infection with H. pylori [",
"      <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/46,77\">",
"       46,77",
"      </a>",
"      ]. In one series, coffee increased dyspepsia in subjects with nonulcer dyspepsia but not in those with DU when compared to controls [",
"      <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/78\">",
"       78",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Clinical experience indicates that food intolerances are common in patients with DU and other acid-peptic and functional gastrointestinal disorders. These symptoms appear to reflect sensitivities to substances in foods; there is no evidence that they are related directly to ulcer formation. Food intolerances are common and highly variable in the general population making rigorous investigation challenging.",
"     </li>",
"     <li>",
"      Although frequently advised in the past, there is no evidence that dietary manipulations, such as a bland diet, enhance healing [",
"      <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/79\">",
"       79",
"      </a>",
"      ]. Frequent feedings, justified on the basis that small meals cause less gastric distension, may lead instead to more sustained stimulation of acid secretion. Bedtime snacks stimulate nocturnal acid secretion.",
"     </li>",
"     <li>",
"      Milk was a mainstay of symptomatic therapy for peptic ulcer because of its soothing nature, until it was shown to be a strong acid secretagogue, largely because of its calcium and protein content [",
"      <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/80\">",
"       80",
"      </a>",
"      ]. Milk stimulates more acid secretion than it buffers and is not an effective antacid. Nevertheless, it appears to reduce acute acid-induced damage in rats [",
"      <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/81\">",
"       81",
"      </a>",
"      ], to protect against cysteamine-induced acute DU in mice [",
"      <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/82\">",
"       82",
"      </a>",
"      ], and, after four days, to reduce histamine-stimulated acid secretion in rats [",
"      <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/83\">",
"       83",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Human milk contains potentially protective factors, including growth factors, surface active phospholipids, and prostaglandin E2. Thus, it is possible that milk has antiulcer actions that override the stimulation of acid secretion. Thus, despite a lack of scientific validation, use of milk should not be discouraged in patients who find it beneficial [",
"      <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/84\">",
"       84",
"      </a>",
"      ], as long as they realize that there is no known therapeutic benefit.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Psychologic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The importance of psychodynamic factors in the genesis of peptic ulcer remains controversial despite decades of study [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. Investigation of the psychodynamic aspects of ulcer disease has been hampered for a variety of reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is difficult to define ulcer occurrence and recurrence and to achieve adequate sampling and blinding. Many retrospective studies are based on self-report about the ulcer history, which could lead to bias favoring association with psychosocial factors.",
"     </li>",
"     <li>",
"      The pathogenesis of ulcer disease is multifactorial, and psychodynamic factors are likely to play a role only in a subset of ulcer patients, which remains undefined.",
"     </li>",
"     <li>",
"      Psychological stress is difficult to measure. Stressful events are only part of the picture; the level of distress also reflects the patient's perception of the stressful event, interpretation of implications, and coping mechanisms.",
"     </li>",
"     <li>",
"      Psychodynamic factors need to be correlated with pathophysiologic mechanisms relating to known variables of importance, such as infection with H. pylori, adequate acid secretory mass, smoking, and NSAID use.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because of these limitations, two lines of evidence strongly implicate psychosocial factors in ulcer pathogenesis. First, several studies have used a prospective design to address methodological limitations [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/85\">",
"     85",
"    </a>",
"    ]. The most useful approach has been to track ulcer incidence (new ulcers) or ulcer recurrence in a defined epidemiological cohort. Using this type of approach, studies over the last 15 years have painted a consistent picture about the importance of several forms of psychological stress as predictors of de novo ulcers incidence or ulcer recurrence. As an example, poorly tolerated stress or depressive symptoms at baseline increase the risk of ulcer development over the next 9 to 15 years [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/85\">",
"     85",
"    </a>",
"    ]. Other psychosocial factors, such as work-related stress, social problems, and PTSD are also predictive of subsequent ulcer disease.",
"   </p>",
"   <p>",
"    Second, several studies have established that peptic ulcer complications become much more prevalent during periods of natural disaster or societal catastrophe. The first such study was the demonstration of a dramatically increased rate of ulcer perforation during the German bombardment of London [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/87\">",
"     87",
"    </a>",
"    ]. Several other studies confirm similar findings following other such events [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/85,88\">",
"     85,88",
"    </a>",
"    ]. In the eight weeks following the Hanshin-Awaji earthquake, the H. pylori prevalence in patients without physical injury who had GU was similar to two control groups with GU unexposed to the stress of the earthquake [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/89\">",
"     89",
"    </a>",
"    ]. This finding contrasts to hospitalized patients with peptic ulcer associated with physical injury in whom H. pylori prevalence was similar to the control population. These data suggest that psychological factors exacerbate both H. pylori and non-H. pylori ulcers to a similar extent. &nbsp;",
"   </p>",
"   <p>",
"    Stress, anxiety, and depression were also observed to impair endoscopic healing [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/90\">",
"     90",
"    </a>",
"    ] and to promote relapse of endoscopically diagnosed ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/66,85\">",
"     66,85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effects of stress seem to be reversible; patients who develop an ulcer following traumatic life events, but who are psychologically stable, tend to do well after the stress has resolved [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathophysiological mechanisms accounting for the effects of stress on the ulcer formation have not been defined. These effects could be mediated by both altered behaviors and by altered physiology. Pathogenic mechanisms for peptic ulcer are multifactorial, a fact that confounds unraveling the link between psychosocial factors and ulcerogenesis. As example, stress increases acid secretion, but the effects are more prominent in patients with DU, compared to controls [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/91\">",
"     91",
"    </a>",
"    ]. As a result, one must consider not only the stressor, but the individual's physiological and psychosocial response to the stress; deleterious effects may only be evident in a subset of predisposed individuals.",
"   </p>",
"   <p>",
"    Lastly, finding a relationship between psychosocial factors and ulcer disease does not establish causality. One study found that anxiety and neuroticism were high in a group of DU patients at the outset, but normalized in relapse-free patients at the end of a 10-year follow-up period [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/92\">",
"     92",
"    </a>",
"    ]. In some cases, psychological features may be the result, not the cause of the disease process.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3265799\">",
"    <span class=\"h3\">",
"     Seasonal factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies have demonstrated a seasonal effect on the incidence of ulcer disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/36/3658/abstract/93,94\">",
"     93,94",
"    </a>",
"    ]. However, the underlying pathophysiologic mechanisms are unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/53/5971?source=see_link\">",
"       \"Patient information: Peptic ulcers (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/31/19954?source=see_link\">",
"       \"Patient information: H. pylori infection (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?0/60/964?source=see_link\">",
"       \"Patient information: Peptic ulcer disease (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/58/14242?source=see_link\">",
"       \"Patient information: Helicobacter pylori infection and treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary malfunction of gastroduodenal secretory, defense, or repair mechanisms is a very uncommon cause of ulcer, if it occurs at all. Most ulcers occur when the normal mechanisms are disrupted by superimposed processes such as Helicobacter pylori (H. pylori) infection and the ingestion of nonsteroidal antiinflammatory drugs (NSAIDs). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Despite the understanding that the majority of peptic ulcer disease (PUD) is related to H. pylori or NSAIDs, gastroduodenal ulcers are still \"peptic\". With very few exceptions, complete pharmacologic inhibition of acid secretion induces ulcer healing and prevents recurrence. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Gastric acid hypersecretion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      High normal or modestly elevated gastric acid secretion appears to be a defining characteristic of patients with duodenal ulcers (DU), whether or not they are infected with H. pylori. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Gastric acid hypersecretion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of DU patients with H. pylori have impaired duodenal bicarbonate secretion that is due to the infection itself. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Duodenal abnormalities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A gastric ulcer (GU) occurring in the stomach proximal to the distal antrum and prepyloric region is usually associated with low-normal or low acid secretion, reflecting a low normal parietal cell mass. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Gastric ulcer'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Host factors appear to be important in predisposing to H. pylori infection and to disease outcomes, such as DU and gastric cancer. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Familial aggregation and genetic factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of risk factors potentially impact the rate of ulcer healing, complications, and the tendency for recurrence. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Factors that influence the course of peptic ulcer'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/1\">",
"      Dutta AK, Chacko A, Balekuduru A, et al. Time trends in epidemiology of peptic ulcer disease in India over two decades. Indian J Gastroenterol 2012; 31:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/2\">",
"      Ohmann C, Imhof M, Ruppert C, et al. Time-trends in the epidemiology of peptic ulcer bleeding. Scand J Gastroenterol 2005; 40:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/3\">",
"      Laine L, Yang H, Chang SC, Datto C. Trends for incidence of hospitalization and death due to GI complications in the United States from 2001 to 2009. Am J Gastroenterol 2012; 107:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/4\">",
"      Bashinskaya B, Nahed BV, Redjal N, et al. Trends in Peptic Ulcer Disease and the Identification of Helicobacter Pylori as a Causative Organism: Population-based Estimates from the US Nationwide Inpatient Sample. J Glob Infect Dis 2011; 3:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/5\">",
"      Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/6\">",
"      Kuipers EJ, Thijs JC, Festen HP. The prevalence of Helicobacter pylori in peptic ulcer disease. Aliment Pharmacol Ther 1995; 9 Suppl 2:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/7\">",
"      Sipponen P, Varis K, Fr&auml;ki O, et al. Cumulative 10-year risk of symptomatic duodenal and gastric ulcer in patients with or without chronic gastritis. A clinical follow-up study of 454 outpatients. Scand J Gastroenterol 1990; 25:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/8\">",
"      el-Omar EM, Penman ID, Ardill JE, et al. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology 1995; 109:681.",
"     </a>",
"    </li>",
"    <li>",
"     Isenberg J, McQuaid K, Laine L, et al. Acid-peptic disorders. In: Textbook of Gastroenterology, 2nd ed, Yamada T (Ed), JB Lippincott, Philadelphia 1995. p.1347.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/10\">",
"      Hirschowitz BI, Simmons J, Mohnen J. Minor effects of Helicobacter pylori on gastric secretion and dose of lansoprazole during long-term treatment in ZE and non-ZE acid hypersecretors. Aliment Pharmacol Ther 2002; 16:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/11\">",
"      Moss SF, Legon S, Bishop AE, et al. Effect of Helicobacter pylori on gastric somatostatin in duodenal ulcer disease. Lancet 1992; 340:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/12\">",
"      Olbe L, Hamlet A, Dalenb&auml;ck J, F&auml;ndriks L. A mechanism by which Helicobacter pylori infection of the antrum contributes to the development of duodenal ulcer. Gastroenterology 1996; 110:1386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/13\">",
"      Laine L, Hopkins RJ, Girardi LS. Has the impact of Helicobacter pylori therapy on ulcer recurrence in the United States been overstated? A meta-analysis of rigorously designed trials. Am J Gastroenterol 1998; 93:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/14\">",
"      Harris AW, Gummett PA, Phull PS, et al. Recurrence of duodenal ulcer after Helicobacter pylori eradication is related to high acid output. Aliment Pharmacol Ther 1997; 11:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/15\">",
"      Collen MJ, Jensen RT. Idiopathic gastric acid hypersecretion. Comparison with Zollinger-Ellison syndrome. Dig Dis Sci 1994; 39:1434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/16\">",
"      McColl KE, el-Nujumi AM, Chittajallu RS, et al. A study of the pathogenesis of Helicobacter pylori negative chronic duodenal ulceration. Gut 1993; 34:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/17\">",
"      Annibale B, De Magistris L, Corleto V, et al. Zollinger-Ellison syndrome and antral G-cell hyperfunction in patients with resistant duodenal ulcer disease. Aliment Pharmacol Ther 1994; 8:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/18\">",
"      Hogan DL, Rapier RC, Dreilinger A, et al. Duodenal bicarbonate secretion: eradication of Helicobacter pylori and duodenal structure and function in humans. Gastroenterology 1996; 110:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/19\">",
"      Wyatt JI, Rathbone BJ, Dixon MF, Heatley RV. Campylobacter pyloridis and acid induced gastric metaplasia in the pathogenesis of duodenitis. J Clin Pathol 1987; 40:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/20\">",
"      Pietroiusti A, Luzzi I, Gomez MJ, et al. Helicobacter pylori duodenal colonization is a strong risk factor for the development of duodenal ulcer. Aliment Pharmacol Ther 2005; 21:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/21\">",
"      Malaty HM, Graham DY, Isaksson I, et al. Are genetic influences on peptic ulcer dependent or independent of genetic influences for Helicobacter pylori infection? Arch Intern Med 2000; 160:105.",
"     </a>",
"    </li>",
"    <li>",
"     Rotter JI. Peptic ulcer. In: The principles and practice of medical genetics, Emery AEH, Rimoin DL (Eds), Churchill Livingstone, New York 1983. p.863.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/23\">",
"      Mertz HR, Peterson WL, Walsh JH. \"Familial hyperpepsinogenemia\" and Helicobacter pylori infection. Am J Gastroenterol 2000; 95:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/24\">",
"      Wilschanski M, Schlesinger Y, Faber J, et al. Combination of Helicobacter pylori strain and tumor necrosis factor-alpha polymorphism of the host increases the risk of peptic ulcer disease in children. J Pediatr Gastroenterol Nutr 2007; 45:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/25\">",
"      Furuta T, El-Omar EM, Xiao F, et al. Interleukin 1beta polymorphisms increase risk of hypochlorhydria and atrophic gastritis and reduce risk of duodenal ulcer recurrence in Japan. Gastroenterology 2002; 123:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/26\">",
"      Garc&iacute;a-Gonz&aacute;lez MA, Lanas A, Savelkoul PH, et al. Association of interleukin 1 gene family polymorphisms with duodenal ulcer disease. Clin Exp Immunol 2003; 134:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/27\">",
"      Hwang IR, Hsu PI, Peterson LE, et al. Interleukin-6 genetic polymorphisms are not related to Helicobacter pylori-associated gastroduodenal diseases. Helicobacter 2003; 8:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/28\">",
"      Sugimoto M, Furuta T, Shirai N, et al. Different effects of polymorphisms of tumor necrosis factor-alpha and interleukin-1 beta on development of peptic ulcer and gastric cancer. J Gastroenterol Hepatol 2007; 22:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/29\">",
"      Garcia-Gonzalez MA, Savelkoul PH, Benito R, et al. No allelic variant associations of the IL-1 and TNF gene polymorphisms in the susceptibility to duodenal ulcer disease. Int J Immunogenet 2005; 32:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/30\">",
"      Robert A, Olafsson AS, Lancaster C, Zhang WR. Interleukin-1 is cytoprotective, antisecretory, stimulates PGE2 synthesis by the stomach, and retards gastric emptying. Life Sci 1991; 48:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/31\">",
"      Garcia-Gonzalez MA, Strunk M, Piazuelo E, et al. TGFB1 gene polymorphisms: their relevance in the susceptibility to Helicobacter pylori-related diseases. Genes Immun 2006; 7:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/32\">",
"      Arisawa T, Tahara T, Shibata T, et al. Association between genetic polymorphisms in the cyclooxygenase-1 gene promoter and peptic ulcers in Japan. Int J Mol Med 2007; 20:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/33\">",
"      R&auml;ih&auml; I, Kemppainen H, Kaprio J, et al. Lifestyle, stress, and genes in peptic ulcer disease: a nationwide twin cohort study. Arch Intern Med 1998; 158:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/34\">",
"      Del Bianco T, Borgoni R, Del Bianco P, et al. Peptic ulcer inheritance in patients with elevated serum pepsinogen group A levels and without infection of Helicobacter pylori. Dig Liver Dis 2000; 32:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/35\">",
"      Nakajima T. Studies on factors affecting healing of gastric ulcer. A prospective, cooperative study in Japan. Am J Gastroenterol 1976; 66:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/36\">",
"      Edgren G, Hjalgrim H, Rostgaard K, et al. Risk of gastric cancer and peptic ulcers in relation to ABO blood type: a cohort study. Am J Epidemiol 2010; 172:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/37\">",
"      Niv Y, Fraser G, Delpre G, et al. Helicobacter pylori infection and blood groups. Am J Gastroenterol 1996; 91:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/38\">",
"      Umlauft F, Keeffe EB, Offner F, et al. Helicobacter pylori infection and blood group antigens: lack of clinical association. Am J Gastroenterol 1996; 91:2135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/39\">",
"      Keller R, Dinkel KC, Christl SU, Fischbach W. Interrelation between ABH blood group 0, Lewis(B) blood group antigen, Helicobacter pylori infection, and occurrence of peptic ulcer. Z Gastroenterol 2002; 40:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/40\">",
"      Martin DF, Montgomery E, Dobek AS, et al. Campylobacter pylori, NSAIDS, and smoking: risk factors for peptic ulcer disease. Am J Gastroenterol 1989; 84:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/41\">",
"      Anda RF, Williamson DF, Escobedo LG, Remington PL. Smoking and the risk of peptic ulcer disease among women in the United States. Arch Intern Med 1990; 150:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/42\">",
"      Korman MG, Hansky J, Eaves ER, Schmidt GT. Influence of cigarette smoking on healing and relapse in duodenal ulcer disease. Gastroenterology 1983; 85:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/43\">",
"      Rosenstock S, J&oslash;rgensen T, Bonnevie O, Andersen L. Risk factors for peptic ulcer disease: a population based prospective cohort study comprising 2416 Danish adults. Gut 2003; 52:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/44\">",
"      Kato I, Nomura AM, Stemmermann GN, Chyou PH. A prospective study of gastric and duodenal ulcer and its relation to smoking, alcohol, and diet. Am J Epidemiol 1992; 135:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/45\">",
"      Kurata JH, Nogawa AN. Meta-analysis of risk factors for peptic ulcer. Nonsteroidal antiinflammatory drugs, Helicobacter pylori, and smoking. J Clin Gastroenterol 1997; 24:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/46\">",
"      Aldoori WH, Giovannucci EL, Stampfer MJ, et al. A prospective study of alcohol, smoking, caffeine, and the risk of duodenal ulcer in men. Epidemiology 1997; 8:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/47\">",
"      Talamini G, Zamboni G, Cavallini G. Antral mucosal Helicobacter pylori infection density as a risk factor of duodenal ulcer. Digestion 1997; 58:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/48\">",
"      Chan FK, Sung JJ, Lee YT, et al. Does smoking predispose to peptic ulcer relapse after eradication of Helicobacter pylori? Am J Gastroenterol 1997; 92:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/49\">",
"      Bardhan KD, Graham DY, Hunt RH, O'Morain CA. Effects of smoking on cure of Helicobacter pylori infection and duodenal ulcer recurrence in patients treated with clarithromycin and omeprazole. Helicobacter 1997; 2:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/50\">",
"      Maity P, Biswas K, Roy S, et al. Smoking and the pathogenesis of gastroduodenal ulcer--recent mechanistic update. Mol Cell Biochem 2003; 253:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/51\">",
"      Savage RL, Moller PW, Ballantyne CL, Wells JE. Variation in the risk of peptic ulcer complications with nonsteroidal antiinflammatory drug therapy. Arthritis Rheum 1993; 36:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/52\">",
"      Hirschowitz BI, Lanas A. Atypical and aggressive upper gastrointestinal ulceration associated with aspirin abuse. J Clin Gastroenterol 2002; 34:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/53\">",
"      Lanas AI, Remacha B, Esteva F, S&aacute;inz R. Risk factors associated with refractory peptic ulcers. Gastroenterology 1995; 109:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/54\">",
"      Sonnenberg A, M&uuml;ller-Lissner SA, Vogel E, et al. Predictors of duodenal ulcer healing and relapse. Gastroenterology 1981; 81:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/55\">",
"      Piper DW, Hunt J, Heap TR. The healing rate of chronic gastric ulcer in patients admitted to hospital. Scand J Gastroenterol 1980; 15:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/56\">",
"      Okada M, Yao T, Fuchigami T, et al. Factors influencing the healing rate of gastric ulcer in hospitalised subjects. Gut 1984; 25:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/57\">",
"      Permutt RP, Cello JP. Duodenal ulcer disease in the hospitalized elderly patient. Dig Dis Sci 1982; 27:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/58\">",
"      van der Voort PH, van der Hulst RW, Zandstra DF, et al. Prevalence of Helicobacter pylori infection in stress-induced gastric mucosal injury. Intensive Care Med 2001; 27:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/59\">",
"      STEIGMANN F, SHULMAN B. The time of healing of gastric ulcers: implications as to therapy. Gastroenterology 1952; 20:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/60\">",
"      Reynolds JC, Schoen RE, Maislin G, Zangari GG. Risk factors for delayed healing of duodenal ulcers treated with famotidine and ranitidine. Am J Gastroenterol 1994; 89:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/61\">",
"      Massarrat S, Eisenmann A. Factors affecting the healing rate of duodenal and pyloric ulcers with low-dose antacid treatment. Gut 1981; 22:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/62\">",
"      Okada M, Yao T, Maeda K, et al. Predictors of duodenal ulcer healing during treatment with cimetidine. Gut 1990; 31:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/63\">",
"      Piai G, Sabbatini F, Minieri M, et al. The influence of severe bulb deformity on duodenal ulcer relapse. Hepatogastroenterology 1990; 37:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/64\">",
"      Van Deventer GM, Elashoff JD, Reedy TJ, et al. A randomized study of maintenance therapy with ranitidine to prevent the recurrence of duodenal ulcer. N Engl J Med 1989; 320:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/65\">",
"      Peterson WL, Barnett C, Walsh JH. Effect of intragastric infusions of ethanol and wine on serum gastrin concentration and gastric acid secretion. Gastroenterology 1986; 91:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/66\">",
"      Armstrong D, Arnold R, Classen M, et al. RUDER--a prospective, two-year, multicenter study of risk factors for duodenal ulcer relapse during maintenance therapy with ranitidine. RUDER Study Group. Dig Dis Sci 1994; 39:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/67\">",
"      Battaglia B, Di Mario F, Dotto P, Naccarato R. Alcohol intake and acute duodenal ulcer healing. Am J Gastroenterol 1990; 85:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/68\">",
"      Reynolds JC. Famotidine therapy for active duodenal ulcers. A multivariate analysis of factors affecting early healing. Ann Intern Med 1989; 111:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/69\">",
"      Tovey FI, Hobsley M, Kaushik SP, et al. Duodenal gastric metaplasia and Helicobacter pylori infection in high and low duodenal ulcer-prevalent areas in India. J Gastroenterol Hepatol 2004; 19:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/70\">",
"      Jayaraj AP, Tovey FI, Clark CG, Hobsley M. Dietary factors in relation to the distribution of duodenal ulcer in India as assessed by studies in rats. J Gastroenterol Hepatol 2001; 16:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/71\">",
"      Tovey FI, Hobsley M, Segal I, Jayaraj AP. Duodenal ulcer in South Africa: home-pounded versus milled maize. J Gastroenterol Hepatol 2005; 20:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/72\">",
"      Kang JY, Yeoh KG, Chia HP, et al. Chili--protective factor against peptic ulcer? Dig Dis Sci 1995; 40:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/73\">",
"      Hollander D, Tarnawski A. Dietary essential fatty acids and the decline in peptic ulcer disease--a hypothesis. Gut 1986; 27:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/74\">",
"      Duggan AE, Atherton JC, Cockayne A, et al. Clarification of the link between polyunsaturated fatty acids and Helicobacter pylori-associated duodenal ulcer disease: a dietary intervention study. Br J Nutr 1997; 78:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/75\">",
"      Aldoori WH, Giovannucci EL, Stampfer MJ, et al. Prospective study of diet and the risk of duodenal ulcer in men. Am J Epidemiol 1997; 145:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/76\">",
"      Cohen S, Booth GH Jr. Gastric acid secretion and lower-esophageal-sphincter pressure in response to coffee and caffeine. N Engl J Med 1975; 293:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/77\">",
"      Brenner H, Rothenbacher D, Bode G, Adler G. Relation of smoking and alcohol and coffee consumption to active Helicobacter pylori infection: cross sectional study. BMJ 1997; 315:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/78\">",
"      Elta GH, Behler EM, Colturi TJ. Comparison of coffee intake and coffee-induced symptoms in patients with duodenal ulcer, nonulcer dyspepsia, and normal controls. Am J Gastroenterol 1990; 85:1339.",
"     </a>",
"    </li>",
"    <li>",
"     Baron HH, Wastell C. Medical treatment. In: Chronic duodenal ulcer, Wastell C (Ed), Butterworths, London 1972. p.117.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/80\">",
"      Ippoliti AF, Maxwell V, Isenberg JI. The effect of various forms of milk on gastric-acid secretion. Studies in patients with duodenal ulcer and normal subjects. Ann Intern Med 1976; 84:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/81\">",
"      Dial EJ, Lichtenberger LM. A role for milk phospholipids in protection against gastric acid. Studies in adult and suckling rats. Gastroenterology 1984; 87:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/82\">",
"      Dai S, Klagsbrun M, Shing YW. Human milk-derived growth factor prevents duodenal ulcer formation. Pediatr Res 1985; 19:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/83\">",
"      Wirbel A, Ducroc R, Garzon B, Geloso JP. Inhibition by cow's milk of histamine-induced gastric acid secretion in the rat. J Pediatr Gastroenterol Nutr 1989; 9:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/84\">",
"      Spiro HM. Is milk all that bad for the ulcer patient? J Clin Gastroenterol 1981; 3:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/85\">",
"      Levenstein S. The very model of a modern etiology: a biopsychosocial view of peptic ulcer. Psychosom Med 2000; 62:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/86\">",
"      Melmed RN, Gelpin Y. Duodenal ulcer: the helicobacterization of a psychosomatic disease? Isr J Med Sci 1996; 32:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/87\">",
"      Spicer CC, Stewart DN, Winser DM. Perforated peptic ulcer during the period of heavy air raids. Lancet 1944; 1:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/88\">",
"      Kanno T, Iijima K, Abe Y, et al. Peptic ulcers after the Great East Japan earthquake and tsunami: possible existence of psychosocial stress ulcers in humans. J Gastroenterol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/89\">",
"      Matsushima Y, Aoyama N, Fukuda H, et al. Gastric ulcer formation after the Hanshin-Awaji earthquake: a case study of Helicobacter pylori infection and stress-induced gastric ulcers. Helicobacter 1999; 4:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/90\">",
"      Holtmann G, Armstrong D, P&ouml;ppel E, et al. Influence of stress on the healing and relapse of duodenal ulcers. A prospective, multicenter trial of 2109 patients with recurrent duodenal ulceration treated with ranitidine. RUDER Study Group. Scand J Gastroenterol 1992; 27:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/91\">",
"      Bresnick WH, Rask-Madsen C, Hogan DL, et al. The effect of acute emotional stress on gastric acid secretion in normal subjects and duodenal ulcer patients. J Clin Gastroenterol 1993; 17:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/92\">",
"      Wilhelmsen I, Berstad A. Reduced relapse rate in duodenal ulcer disease leads to normalization of psychological distress: twelve-year follow-up. Scand J Gastroenterol 2004; 39:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/93\">",
"      Manfredini R, De Giorgio R, Smolensky MH, et al. Seasonal pattern of peptic ulcer hospitalizations: analysis of the hospital discharge data of the Emilia-Romagna region of Italy. BMC Gastroenterol 2010; 10:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/36/3658/abstract/94\">",
"      Sonnenberg A, Wasserman IH, Jacobsen SJ. Monthly variation of hospital admission and mortality of peptic ulcer disease: a reappraisal of ulcer periodicity. Gastroenterology 1992; 103:1192.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-27.109.116.13-BBD231414A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_36_3658=[""].join("\n");
var outline_f3_36_3658=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Helicobacter pylori",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Nonsteroidal antiinflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Other factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Gastric acid hypersecretion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Duodenal abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Gastric ulcer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      GENETIC, ENVIRONMENTAL, AND PSYCHOLOGICAL RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Familial aggregation and genetic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Factors that influence the course of peptic ulcer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Smoking",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Nonsteroidal antiinflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Characteristics of the patient",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Characteristics of the ulcer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Alcohol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Diet",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Psychologic factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3265799\">",
"      - Seasonal factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44679?source=related_link\">",
"      Association between Helicobacter pylori infection and duodenal ulcer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/18/13609?source=related_link\">",
"      Clinical manifestations of peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/42/19113?source=related_link\">",
"      Epidemiology and etiology of peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6745?source=related_link\">",
"      NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/21/40282?source=related_link\">",
"      Overview of the complications of peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42281?source=related_link\">",
"      Overview of the natural history and treatment of peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/44/4809?source=related_link\">",
"      Pathophysiology of and immune response to Helicobacter pylori infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/31/19954?source=related_link\">",
"      Patient information: H. pylori infection (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/58/14242?source=related_link\">",
"      Patient information: Helicobacter pylori infection and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/60/964?source=related_link\">",
"      Patient information: Peptic ulcer disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/53/5971?source=related_link\">",
"      Patient information: Peptic ulcers (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18776?source=related_link\">",
"      Stress ulcer prophylaxis in the intensive care unit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19466?source=related_link\">",
"      Unusual causes of peptic ulcer disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_36_3659="Efficacy pancreatic drainage";
var content_f3_36_3659=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F78326&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F78326&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Incidence of pancreatitis according to the type of pancreatic drainage",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Nasopancreatic drainage",
"       </td>",
"       <td>",
"        0 of 98 (0 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Pancreatic stenting",
"       </td>",
"       <td>",
"        1 of 50 (2 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Any drainage",
"       </td>",
"       <td>",
"        1 of 148 (0.7 percent)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        No drainage",
"       </td>",
"       <td>",
"        2 of 16 (12.5 percent)*",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * p&lt;0.003 for pancreatic duct drainage versus no drainage",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Elton E, et al. Gastrointest Endosc 1998; 47:240.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_36_3659=[""].join("\n");
var outline_f3_36_3659=null;
var title_f3_36_3660="Predictors of survival";
var content_f3_36_3660=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F56650&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F56650&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Predictors of survival in patients with advanced cancer under palliative care",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Index Survival",
"       </td>",
"       <td class=\"subtitle1\">",
"        Value",
"       </td>",
"       <td class=\"subtitle1\">",
"        Median",
"       </td>",
"       <td class=\"subtitle1\">",
"        References",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Karnofsky Performance Status",
"       </td>",
"       <td>",
"        10 to 20",
"       </td>",
"       <td>",
"        7 to 16 days",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Evans 1985, Maltoni 1994, Maltoni 1995; Reuben 1998, Morita 1999, Llobera 2000, Bruera 1992",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        30 to 40",
"       </td>",
"       <td>",
"        8 to 50 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;50",
"       </td>",
"       <td>",
"        50 to 90 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anorexia",
"       </td>",
"       <td>",
"        Present",
"       </td>",
"       <td>",
"        &lt;58 days",
"       </td>",
"       <td>",
"        Maltoni 1995, Llobera 2000, Bruera 1992",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Confusion",
"       </td>",
"       <td>",
"        Present",
"       </td>",
"       <td>",
"        &lt;38 days",
"       </td>",
"       <td>",
"        Llobera 2000, Bruera 1992",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dysphagia",
"       </td>",
"       <td>",
"        Present",
"       </td>",
"       <td>",
"        &lt;30 days",
"       </td>",
"       <td>",
"        Maltoni 1995",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dyspnea",
"       </td>",
"       <td>",
"        Present",
"       </td>",
"       <td>",
"        &lt;30 days",
"       </td>",
"       <td>",
"        Maltoni 1995",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Xerostomia",
"       </td>",
"       <td>",
"        Present",
"       </td>",
"       <td>",
"        &lt;50 days",
"       </td>",
"       <td>",
"        Bruera 1992",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Physician estimate",
"       </td>",
"       <td>",
"        3 mos",
"       </td>",
"       <td>",
"        30 days",
"       </td>",
"       <td>",
"        Parkes 1972, Heyse-Moore 1987, Christakis 2000",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_36_3660=[""].join("\n");
var outline_f3_36_3660=null;
var title_f3_36_3661="Survival in asymptomatic AS";
var content_f3_36_3661=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F53975&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F53975&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Survival in asymptomatic aortic stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 384px; height: 241px; background-image: url(data:image/gif;base64,R0lGODlhgAHxANUAAP///4CAgP4AAAAAAEBAQMDAwCAgIDAwMNDQ0FBQUBAQEKCgoPDw8HBwcLCwsODg4GBgYJCQkP+wsP4QEP+AgP5gYP5AQP/AwP/w8P/g4P+goP/Q0P5QUP4gIP4wMP+QkH8AAP5wcD8AAL4AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAACAAfEAAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKztLW2t7i5uru8vb6/wMGuCAVHDAsBCwzCzKsPCwoDRwcDBAMHzdmnAQPdRg4DCQAJAw5DBQHp6iAjAgIeFvHxHBT19hIX+fkb2v2C3kW4BQAg8Jw6dSJAuFvIsKFDh0UyYPBHcQ5AIgULJkknRJ8+DfbsyZPX4SFDCRVTurk4JMKABgAaDIighOMVk+4sZFDJ08yD/wLdCjwAYA3AgwEGChgYMHTjQC8YKCykMLGn1S/cug0YWBTAgqUGFiyx+SWDBXcddl5dW4csGAklPVRlS/eNWzAYPAiYUAFl3b9q7oLZMGEhX7+AE4sRjFdChcLuJnD4wE+x5S2MxziGHNkCBXyXQ0/JXObCBw6cI/cVzZoJaTQbJFCwwPlw5da4hbxms9nw7dysd7vpjRi4aOFvKgioYLw18uF7Vze//LwNYcPSp/+tbr236uLarXKH4z06+PAVx8spfxh9SvV02Ped654ZfDvsf9d3RKC/fwIwpXEfHr3JtR8kWiVIQGBPMZLXO/QdyMuAejwogAX0aHCBRBIigv9AAv4FiAaFFeIUIQBqddgHNVotKGCDjmCQwQUgcXAWTir6McAC0kAAoxXHBBDBMjX9OAkGOGmQIx8DKFVAAy5ewQA11ihAJBIkCoJBhBoI0MGSexgQAATdiIMFUNhYU4xToZSkJJh4IIAAAwkkcCWQ1BxgAARjGblJlwzBWUcBd2bBAAQKLHXAlegcFAABfm7SkKB0WAOBOVq4NBA5DTZ6EKSiqGUSpW0swKIBNFVRFI8HFECNWGySMiqpbSBgTZRTdNVANGL2qUoG7pxIKxmmdqNAqiNGKgqSAoQwbBqWYsrgKhe4c4EQMj47BqFuZElJCA4Jq+2ZDBBTwLkITLv/CrMMcTCuF01a06K6q3AIwAbufPAuFwE8cxCsycrygTv67XsFt214qwkHe71pMBbRsqFwJhlA1oHDD1NRLFLInjExxRqUlFOGF4ibcRK2VkMvLYA+dHITGx+7ci0b0EiBje68zETEa3w8Ss46K4GwxMraEmjQR/TXbdG1HI10QLjOzAtOAgQtU4hS70J10PJ2E3UZPrNCtdNPY8W0L2MvNCyUWL/416w5dq2y23XBDacB0np8tlXunKfiAV+TEXYvyjGnRIrAsU2NmQFfJkHaQBvXtQHp0n0Z5AJgXHaslxVcRMtqt9ZAAAgkWiiQyDA9eEUQtabAAgkooICIV5Re/40BvrqXYuSiNWlAAo9qsVTluR8ItOd//b4VlFkggNRSjAPgqTqgSjhpaC4p8IABtFeBpqs7GuRo9cafJBoCDzAwtBXOL6gRlns3V/iwXS3lADVrwr/k4xPQLw0ACKDG64qnosL4LWirW4tU3HUZB/SLdFnbD7AEgLi/yKRJCeCT5XLEMApYRgEQaFXwNqiix1VNMfEqAAQCN4YEsoVgiiGAnsjRMTO4cC28IwLy/GG7a5xOcPHTztjYUgDikVBFYztgPxgApQ/lzYZB7ND8KugPcjQJAtGD4r5MuBAqZmMmBEAHCxcTxQ5dryLlCCMBsgi2MkqIHwvpwEgqEBIN6f/Di7VAVKLCd8RnTRBzrbsFnQYwu565UUU7qZk+PhASG8mDM7mQ09I2xwSXzUJpCTvkySwpi/tNkpJPyOEr5DbGMNyQVGlTBdv60702gjKUQzwFAeTUFKK9EguiFEUaNamFUz6Mk6BYSoLm1rhbVgGYn/hQotpWTGPi8oSjWED+DOlMLeTyFwxYiup4WU0iuENzwLDiNrt5hT9SUBjg4BQByUkFQEVzTQ54IhUYoIB0bIUI00sH+dh5TGiConrMwwI3CAAWgOXzUdzkJwBiaQmgDJONUGBeo241TSP4EmkMrYStlrlGI0qhK7q5Z5EU+oVrSkKaWiAGEX5SS/2RtAv/Jo3Eh5ipt5fCFJmPEKbXImhTKtgNQRCtaU/BEFNFJKCVzRwqF4qaCETRVItK9QJTEUFKnka1n6H7xUX5eUZHMHGWCZAnEK9KVH82wooqDCoZyVpSszICjGK0Klt9CkjI2SGNBVijXOcqhbratQ56XArAhMrXOkw1DYMs5F4Lq4bDouGHSWUsHBx7Bhkqw5aSnQNO13DBAUCgoq7MrBw2uwYGOOBWixVtJxDQAGFqMLKqHYU1uOdRqMbWFBEQK2FvK4qfEEGSfeRtJ7hBlAVhErbC5QRxlXbcKzgARAmobUASmtxFcMNVrQKcFmQoQMjqhrrVTURWFKSFpuBvpOH9/8QC/sNKLtDTSuL7FHjTqwoyDfag+6QvLlQKgCnxEb36zUX9kNKfwVp0vgEGRUDZa+DpJpgnW31wKSIs4VFQuMKhuDCGP6HhDQ8XwR5mRYdDrIkRkxgTJj6xJVKsYkqwuMWSeDGMISHjGTuixjZmBI5zrIgd8xgRPv6xIYIsZEIQuciCODKSAaHkJfuhyU4WgwMj0FIhBOmyAI4yJmRyANlVmUrXWKeWKcEAQgLAJbRL5zjKkeUxUwIoC4IzRu75PvxCylF4zrOe98znPvv5z4AOtKAHTehCG/rQiE50oEEbCDnLeQgZEan08NwfRVtan3e+tKYflelNK7rSnr40qP9Dnej8CsJ52FBzS14Sk5m0+ZN2CDKRZQ1iNtiPHGIpylGSspQqO1gOs651L4U97DtAmQkBJGSAuvIVpDT413EItrGJnQVaW5jao8H2Faw97W6LosbSjrW2rcDtDI8bCuFuy7mpUG5QnGsO775DvAfF6DjMmw73drO+983vfvubCVf2rhnUV8sHREBIAhcDAtJhYGL42gyNyluQ1s2EcxEpSEN6g8GTYWVkYFkTYMZGGwqgTiF0TeRqSJCIbEfxIji0G0+xHUHhwKMm9RfM8GUDjxSgVwCEfBNqJoduy6CVBjmAAdm0uRrE4rz/+Rzma/Atj1w0vDg8IBo2RxNRlK7/hl1fKehszkSkW36E9w2h123YtW5mJ+mlx84czjMA9N7gH5v7V0+vVYNLuuzqsZeYzm0PTODR7AahA7AcZk9DA7oslu+9qg0R0J6a+osoRSXclJ51QDQe4PdMEF4mNRRQ22WSd8RaA1bjhXobvNE+ggQeDXJrkqbWTHYizF5Nn3d1JnatFKaMnEyfFQI5xBSAeovhAVRKxwN+okLPPryFwBu+EOx3XjaYixpDYhX4nl2GXWveSrxHuyaaHZaVJEgIw6y99IaZv8SbwQHCnKUQkj1AOEw+JrxSPxHIXznyc//fABiAAjiABFiABniACJiACphj5nIuRbRe0vUEpyV//3LAPLbyf3kQUGwVe2HUL1VwFAfggXJQFEABXiUYBie4dXxFDMBXROgwFMhwWg1wKBRIcgByJ2RCAAvAeQXgAEy3QjOoG8iggx9iJ0XwACsEAekSg3WSLuiAACj1XASQKiR4TzF4gytUOUhIAEroFQHwXNEFADkYKVc4g1k4f0C4DOjgACtkDmO4dWCYLl9lauykEde1dXJHSLMFAOkkE9FDDdwDFNFAAFcXggogct3AdwZADXlXiAEgO3gIiK4XDV8YDjIBE1XIFc+jh0hhFIf4iAoQiZ0IiCw0W0vBc53oiIc4ifKCfAQmirhjAPXUWj1lhzaXiSrIKQGwFPh0T/9AESAuYQ4ykS4qc4fEdGae9Sjx8j/U4HqYQg7L0GUqeIK4WBQu4SNq0hXNmIJJIw3UKA3B2GoLZ3MycS4ipY3SIDs+8nzdZIvFUI3SYA0H0YsDkYJ3aIzuY3PHyA0+onxdURR3qIIqCI/rp4mu14/98o/e+HpDQJD32CQPaY5PoZAAlACnyI7O5I7TeE/WGA49mHcnmILOkwBKEYoAUIz6iCuo5gBPkjImJw0BqSlqRpDfeHgHwJIN4JIbGVbjkHMvWZAqOJIl6XrFcF1AwZMUqYN5NQARWE0aSZAEIUzRE5KS1mwHUDkoWQzHyIcscgAPQJEBiX/hsAw0yZH/cz9OifiV/6OQoQhCRQCVVpkuEbl1oUiRVlR+CxgHzoOReVkJDtSXgBmYgjmYhFmYhnmYiJmYirmYjNmYjvmYkBmZkjmZlFmZlnmZmJmZoBAEADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Kaplan-Meier analysis shows survival without valve replaement for 123 patients with valvular aortic stenosis who were intially asymptomatic.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Otto CM, Burwash IG, Legget ME, et al. Circulation 1997; 95:2262.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_36_3661=[""].join("\n");
var outline_f3_36_3661=null;
var title_f3_36_3662="Survival in beta thal major";
var content_f3_36_3662=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F75362&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F75362&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Survival beyond 12 years of age in beta thalassemia major",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 446px; height: 350px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This graph shows the survival beyond age 12 of four consecutive 10-year cohorts of children surviving to age 12 with beta thalassemia major. Cohorts are dated from time of birth.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data reproduced with permission by Modell, B, et al, Lancet 2000; 355:2051.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_36_3662=[""].join("\n");
var outline_f3_36_3662=null;
var title_f3_36_3663="Branching cals";
var content_f3_36_3663=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F66876&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F66876&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mammogram clustered calcifications B",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Magnified craniocaudal mammogram showing linear branching calcifications in a segmental distribution (red arrow). Clustered microcalcifications such as these are highly suggestive of carcinoma, the linear branching is suggestive of a ductal lesion. Biopsy confirmed a high-grade ductal carcinoma in situ (DCIS).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lisa E Esserman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_36_3663=[""].join("\n");
var outline_f3_36_3663=null;
